name: Patients who have a diagnosis of rhabdomyolysis at any time during the performance period


name: Patients who are breastfeeding at any time during the performance period


name: Hospitalized patients with newly diagnosed cva considered for endovascular stroke treatment


name: Patients who are transferred from one institution to another with a known diagnosis of cva for endovascular stroke treatment


name: Surgical procedures that included the use of silicone oil (G9756)


name: Patients who had documentation of use of anticoagulant medications overlapping the measurement year


name: Documentation stating the patient has had a diagnosis of bipolar disorder


name: Documentation of medical reason(s) for prescribing or dispensing antibiotic (e.g., intestinal infection, pertussis, bacterial infection, lyme disease, otitis media, acute sinusitis, acute pharyngitis, acute tonsillitis, chronic sinusitis, infection of the pharynx/larynx/tonsils/adenoids, prostatitis, cellulitis/ mastoiditis/bone infections, acute lymphadenitis, impetigo, skin staph infections, pneumonia, gonococcal infections/venereal disease (syphilis, chlamydia, inflammatory diseases [female reproductive organs]), infections of the kidney, cystitis/uti, acne, hiv disease/asymptomatic hiv, cystic fibrosis, disorders of the immune system, malignancy neoplasms, chronic bronchitis, emphysema, bronchiectasis, extrinsic allergic alveolitis, chronic airway obstruction, chronic obstructive asthma, pneumoconiosis and other lung disease due to external agents, other diseases of the respiratory system, and tuberculosis


name: Patients with a diagnosis or past history of total colectomy or colorectal cancer


name: Documentation of system reason(s) for not prescribing a long-acting inhaled bronchodilator (e.g., cost of treatment or lack of insurance)


name: Documentation of medical reason(s) for not prescribing a long-acting inhaled bronchodilator (e.g., patient intolerance or history of side effects)


name: Long-acting inhaled bronchodilator prescribed


name: Physician service or other qualified health care professional for the evaluation and management of a beneficiary's acute change in condition in a nursing facility. this service is for a demonstration project


name: This code is for the onsite acute care treatment of a nursing facility resident for a uti; may only be billed once per day per beneficiary


name: This code is for the onsite acute care treatment a nursing facility resident with a skin infection; may only be billed once per day per beneficiary


name: This code is for onsite acute care treatment of a resident with copd or asthma; may only be billed once per day per beneficiary


name: This code is for onsite acute care treatment of a nursing facility resident with chf; may only be billed once per day per beneficiary


name: This code is for onsite acute care treatment of a nursing facility resident with pneumonia; may only be billed once per day per beneficiary


name: Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved coms innovation center demonstration project, which requires at least 2 of the following 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology


name: Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a detailed history; a detailed examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology


name: Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: an expanded problem focused history; an expanded problem focused examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology


name: Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a problem focused history; a problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology


name: Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology


name: Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology


name: Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a detailed history; a detailed examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate severity. typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology


name: Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: an expanded problem focused history; an expanded problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology


name: Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology


name: Telehealth consultation, critical care, subsequent, physicians typically spend 50 minutes communicating with the patient and providers via telehealth


name: Telehealth consultation, critical care, initial , physicians typically spend 60 minutes communicating with the patient and providers via telehealth


name: Care management services for behavioral health conditions, at least 20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales, behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes, facilitating and coordinating treatment such as psychotherapy, pharmacotherapy, counseling and/or psychiatric consultation, and continuity of care with a designated member of the care team.


name: Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service)


name: Subsequent psychiatric collaborative care management, first 60 minutes in a subsequent month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional, with the following required elements: tracking patient follow-up and progress using the registry, with appropriate documentation, participation in weekly caseload consultation with the psychiatric consultant, ongoing collaboration with and coordination of the patient's mental health care with the treating physician or other qualified health care professional and any other treating mental health providers, additional review of progress and recommendations for changes in treatment, as indicated, including medications, based on recommendations provided by the psychiatric consultant, provision of brief interventions using evidence-based techniques such as behavioral activation, motivational interviewing, and other focused treatment strategies, monitoring of patient outcomes using validated rating scales, and relapse prevention planning with patients as they achieve remission of symptoms and/or other treatment goals and are prepared for discharge from active treatment.


name: Initial psychiatric collaborative care management, first 70 minutes in the first calendar month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional, with the following required elements: outreach to and engagement in treatment of a patient directed by the treating physician or other qualified health care professional, initial assessment of the patient, including administration of validated rating scales, with the development of an individualized treatment plan, review by the psychiatric consultant with modifications of the plan if recommended, entering patient in a registry and tracking patient follow-up and progress using the registry, with appropriate documentation, and participation in weekly caseload consultation with the psychiatric consultant, and provision of brief interventions using evidence-based techniques such as behavioral activation, motivational interviewing, and other focused treatment strategies.


name: Resource-intensive services for patients for whom the use of specialized mobility-assistive technology (such as adjustable height chairs or tables, patient lift, and adjustable padded leg supports) is medically necessary and used during the provision of an office/outpatient, evaluation and management visit (list separately in addition to primary service)


name: Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate)


name: Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result


name: Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion


name: Skilled services of a licensed practical nurse (lpn), in the training and/or education of a patient or family member, in the home health or hospice setting, each 15 minutes


name: Skilled services of a registered nurse (rn), in the training and/or education of a patient or family member, in the home health or hospice setting, each 15 minutes


name: Skilled services of a licensed practical nurse (lpn) for the observation and assessment of the patient's condition, each 15 minutes (the change in the patient's condition requires skilled nursing personnel to identify and evaluate the patient's need for possible modification of treatment in the home health or hospice setting)


name: Skilled services of a registered nurse (rn) for the observation and assessment of the patient's condition, each 15 minutes (the change in the patient's condition requires skilled nursing personnel to identify and evaluate the patient's need for possible modification of treatment in the home health or hospice setting)


name: Dialysis procedure with single evaluation by a physician or other qualified health care professional for acute kidney injury without esrd


name: Dialysis procedure at a medicare certified esrd facility for acute kidney injury without esrd


name: Face-to-face home health nursing visit by a rural health clinic (rhc) or federally qualified health center (fqhc) in an area with a shortage of home health agencies; (services limited to rn or lpn only)


name: Implantable/insertable device, not otherwise classified


name: Hygienic item or device, disposable or non-disposable, any type, each


name: Belt, strap, sleeve, garment, or covering, any type


name: Supplies for maintenance of insulin infusion catheter, per week


name: Non-excepted service provided at an off-campus, outpatient, provider-based department of a hospital


name: Ventricular Assist Devices (CMS Temporary Codes)


name: Chemotherapy Administration(CMS Temporary Codes)


name: Prosthetic Implants - Miscellaneous Orthotic or Prosthetic Component or Accessory


name: Additional Incontinence and Ostomy supplies


name: Evaluation of adverse drug event history


name: Evaluation of medication-related care plan


name: Documentation of medication-related goals


name: Emergency medical treatment and active labor act medical screening examination


name: Recommendation to change medication to lower cost therapeutic equivalent


name: Recommendation to monitor patient satisfaction


name: Recommendation to monitor medication adherence


name: Education about medication intake during lactation


name: Education about timing of medication administration


name: Education about genetic predispostion to disease


name: Education about point of care laboratory measurement device


name: Education about safe disposal of medication


name: Referral for high risk medication monitoring


name: Targeted medication therapy review without patient present


name: Development of medication-related action plan with patient


name: Development of medication-related goals with patient


name: Medication care plan discussed with primary care provider


name: Emergency department healthcare professional


name: Education about automatic medication dispensing system


name: Education about elastomeric infusion pump


name: Revision of reconstruction of head of left radius


name: Revision of reconstruction of head of right radius


name: Gender, age, AFP-L3, α fetoprotein and des-carboxy-prothrombin score (assessment scale)


name: Hemiarthroplasty of head of right humerus


name: Counseling about diagnositic imaging findings


name: Excision of Soft Tissue Lesions - dental


name: Special stains for microorganisms - dental


name: {6 (0.4 ML adalimumab 100 MG/ML Auto-Injector [Humira]) } Pack [Humira Pen 40 MG/0.4 ML Starter Pack - Crohn's Disease]


name: {4 (0.4 ML adalimumab 100 MG/ML Auto-Injector [Humira]) } Pack [Humira Pen 40 MG/0.4 ML Starter Pack - Psoriasis]


name: {3 (0.8 ML adalimumab 100 MG/ML Prefilled Syringe [Humira]) } Pack [Humira Prefilled Syringe 80 MG/0.8 ML Starter Pack - Pediatric Crohn's Disease]


name: nystatin 50000000 units compounding powder


name: CDISC SDTM Device-In-Use Response Terminology


name: Relief Redness Reliever and Lubricant Eye Drops


name: benzoyl peroxide 65 % to 82 % MISCELL POWDER (GRAM)


name: Endoscopic sphincterotomy and papillotomy


name: BENZOCAINE 5 g in 100 mL TOPICAL GEL [Pleasure Balm Kama Sutra]


name: Thuja occidentalis / arbor vitae homeopathic preparation


name: desonide, micronized MISCELL POWDER (GRAM)


name: Local anesthesia in conjunction with dental operative or surgical procedures


name: pyrithione zinc 48 % MISCELL LIQUID (GRAM)


name: S100 Calcium Binding Protein A7 Measurement


name: Bupivacaine Hydrochloride Monohydrate, compounding powder


name: deoxycholic acid 98 % MISCELL POWDER (GRAM)


name: Dexamethasone 1.5 MG Oral Tablet includes 7, 11, 21, 35 & 51 Day Packs


name: aldosterone 97.5 % MISCELL POWDER (GRAM)


name: beta 1,3 glucan 91 % MISCELL POWDER (GRAM)


name: amifampridine 98 % MISCELL POWDER (GRAM)


name: hyaluronate sodium 94 % MISCELL POWDER (GRAM)


name: resveratrol greater than 98 % MISCELL POWDER (GRAM)


name: zinc chloride 100 % MISCELL GRANULES (GRAM)


name: estradiol hemihydrate, micronized 100 % MISCELL POWDER (GRAM)


name: GLYCERIN 10 g in 50 mL TOPICAL CREAM [Ato Pollen]


name: emulsifying wax 100 % MISCELL WAX (GRAM)


name: Cyanocobalamin/Levomefolate Calcium/Pyridoxine 2 MG-1.13 MG-25 MG Oral Tablet [FOLTX]


name: Aloe Vera Topical application Solution [COATS ALOE LIQUID]


name: Similac Total Comfort with Iron Powder for Suspension


name: Bupivacaine Hydrochloride;Methylprednisolone Acetate;Povidone Iodine 0.5%; 40 MG/1 ML; 10% Multiple Routes Kit


name: VOPAC GB Cream Compounding Preparation Kit


name: Humira 100 MG/ML 0.8 ML Prefilled Syringe and Humira Prefilled Syringe 80 MG/0.8 ML Starter Pack - Pediatric Crohn's Disease


name: DIMETHICONE 5%/TRIAMCINOLONE ACETONIDE 0.1% CREAM,KIT


name: CAPSAICIN 0.025% CREAM/DICLOFENAC NA 75MGX60 TAB,EC KIT


name: Active-Prep III 10%-20%-2% Kit for Compounding


name: AVOBENZONE 3 g in 100 mL / OCTINOXATE 5 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 2.4 g in 100 mL / OXYBENZONE 5 g in 100 mL TOPICAL CREAM [Active Radiance Day Moisture SPF 30]


name: OCTISALATE 3 g in 100 mL / ZINC OXIDE 6.8 g in 100 mL TOPICAL CREAM [Long Wear Makeup Broad Spectrum SPF 20 Nude Jafra]


name: TITANIUM DIOXIDE 0.048 g in 1 g / ZINC OXIDE 0.093 g in 1 g TOPICAL LOTION [Epionce Daily Shield Tinted SPF 50]


name: TITANIUM DIOXIDE 60 mg in 1 g / ZINC OXIDE 60 mg in 1 g TOPICAL LOTION [Sunstation All-Natural SPF 30 Sunscreen]


name: ZINC OXIDE 22 g in 100 g TOPICAL STICK [TRADER JOE S MINERAL SUNSCREEN]


name: OCTINOXATE .07575 g in 1 mL / OXYBENZONE .06 g in 1 mL / OCTISALATE .0505 g in 1 mL / OCTOCRYLENE .0525 g in 1 mL / AVOBENZONE .03237 g in 1 mL TOPICAL LOTION [PRO TRIPLE PROTECTION FACTOR FACE AND BODY BROAD SPECTRUM SPF 30 SUNSCREEN]


name: Benzethonium Chloride 1.8 mg in 1 mL TOPICAL LIQUID [New Skin Bandage]


name: BUSERELIN ACETATE .99 g in 1 g NOT APPLICABLE POWDER [AX Pharmaceutical]


name: Guanabenz Acetate 4.95 g in 5 g NOT APPLICABLE POWDER [AX Pharmaceutical]


name: ORLISTAT 495 g in 500 g NOT APPLICABLE POWDER [X]


name: ZINC OXIDE 8.82 g in 90 mL TOPICAL LIQUID [Stout Daily SPF for Men]


name: BENAZEPRIL HYDROCHLORIDE 49.5 g in 50 g NOT APPLICABLE POWDER [X]


name: SODIUM PHOSPHATE, DIBASIC, ANHYDROUS 852 mg / POTASSIUM PHOSPHATE, MONOBASIC 155 mg / SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 130 mg ORAL TABLET [Phospho-Trin 250 Neutral]


name: GLYCERIN 1.12 mg in 1 mL / DIMETHICONE 0.75 mg in 1 mL TOPICAL CREAM [Shine Control Matte Effect Cream]


name: GLYCERIN 5 mg in 1 mL TOPICAL GEL [Shine Control Sebum Regulating Gel]


name: AVOBENZONE 25 mg in 1 mL / OCTINOXATE 30 mg in 1 mL / OCTISALATE 30 mg in 1 mL / TITANIUM DIOXIDE 12.5 mg in 1 mL TOPICAL LOTION [DermacinRx Skin Moisturizing Ultra SPF 50 Sunscreen]


name: CATHETER FOLEY 3-WAY 18FR 5ML BARD #0119L18


name: CATHETER,FOLEY 16FR 5/10ML POIESIS #10016


name: CATHETER,FOLEY 2-WAY SILICONE COUDE 16FR 15ML COLOPLAST#AA6316


name: CATHETER,FOLEY SILICONE 24FR 10ML M#DYND11506


name: CATHETER,INTERMITTENT 14FR FEMALE COLOPLAST #28814


name: CATHETER,INTERMITTENT,MAGIC3 14FR ROCHESTER #53514


name: CENTRAL LINE DRESSING CHANGE KIT,DEROYAL #47-324


name: DRESSING,MEDLINE ISLAND 2IN X 2IN #MSC3222


name: DRESSING,PURACOL 2IN X 2IN MEDLINE #MSC8522


name: DRESSING,PURACOL 4IN X 4.25IN MEDLINE#MSC8544


name: DRESSING,THERABOND 3D 6IN X 96IN A#3DAW696


name: TRACH ANTI-DISCONNECT DEVICE,SHILEY #ADD


name: Niacinamide 2.4 g in 120 mL / PANTHENOL 0.12 g in 120 mL / ADENOSINE 0.04 g in 120 mL TOPICAL LIQUID [VITA VOLU 101 ESSENCE]


name: Niacinamide 3.6 g in 180 mL / Adenosine 0.07 g in 180 mL TOPICAL LIQUID [VITA VOLU VOLUME BOOSTER]


name: GLYCERIN 6.25 mg in 1 mL / DIMETHICONE 2.18 mg in 1 mL TOPICAL CREAM [Shine Control Moisturizing Matte Effect Cream]


name: {6 (0.4 ML adalimumab 100 MG/ML Auto-Injector) } Pack


name: {4 (0.4 ML adalimumab 100 MG/ML Auto-Injector) } Pack


name: {3 (0.8 ML adalimumab 100 MG/ML Prefilled Syringe) } Pack


name: Cholecalciferol/Chromium/Cyanocobalamin/Pyridoxine/Selenium/Zinc Sulfate 800 IU-0.2 MG-2 MG-100 MG-0.2 MG-10 MG Oral Capsule [T-SUPPORT MAX]


name: Ensure Pre-Surgery Clear Solution (Artic Chill)


name: Ensure Surgery Immunonutrition Shake (Vanilla)


name: Leader PulmoNeb LT Compressor Nebulizer System


name: RITE AID One Daily Prenatal with DHA Combo Pack


name: Glucerna with Carbsteady 1.0 Cal Vanilla


name: Glucerna with Carbsteady 1.2 Cal Vanilla


name: Glucerna with Carbsteady 1.5 Cal Vanilla


name: SOLVATE SWEET SF Compounding Syrup Vehicle (Wild Cherry)


name: amino acid/prot hydroly/selenium/dextrose/bioflav/blueberry 80 mg-46 mg-33 mg-69 mg-46 mg ORAL CAPSULE


name: {24 (ethinyl estradiol 0.02 MG / norethindrone acetate 1 MG Chewable Tablet) / 4 (ferrous fumarate 75 MG Oral Tablet) } Pack [Mibelas 24 Fe Chewable 28 Day]


name: Similac Advance with Iron Pre-measured Powder Singles Powder for Suspension


name: Similac Go-and-Grow Sensitive Non-GMO with Iron Powder for Suspension


name: Similac NeoSure with Iron Ready-to-Feed Suspension


name: compression panty, large-extra large MISCELL EACH


name: compression panty, small-medium MISCELL EACH


name: EleCare Jr Hypoallergenic Powder for Suspension (Banana)


name: EleCare Jr Hypoallergenic Powder for Suspension (Chocolate)


name: silicone adhesive 10 cm X 12 cm TOPICAL SHEET (EA)


name: subcutaneous bolus insulin patch pump, 200 unit, disposable 2 unit MISCELL EACH


name: subcut bolus insulin patch pump,200 unit,disposabl


name: Homosalate 40 mg in 1 mL / Octisalate 40 mg in 1 mL / Avobenzone 30 mg in 1 mL / Oxybenzone 30 mg in 1 mL / Octocrylene 20 mg in 1 mL TOPICAL LIQUID [Skin Pharmacy Advanced Sun Therapy Broad Spectrum SPF 30 Sun]


name: TITANIUM DIOXIDE 129.3 mg in 1 mL / ZINC OXIDE 108.9 mg in 1 mL TOPICAL CREAM [Tinted Sunscreen Cream SPF 30 4-Deep Amber]


name: homosalate 100 mg in 1 mL / octisalate 50 mg in 1 mL / avobenzone 30 mg in 1 mL / octocrylene 20 mg in 1 mL / oxybenzone 50 mg in 1 mL TOPICAL LOTION [SkinPharmacy Advanced Anti-Aging Therapy Glycolic Day Moisturizer SPF 30]


name: TRILOSTANE 9.9 kg in 10 kg NOT APPLICABLE POWDER [X]


name: {21 (ribociclib 200 MG Oral Tablet) } Pack


name: {21 (ribociclib 200 MG Oral Tablet [Kisqali]) } Pack [Kisqali 200 MG Daily Dose Carton]


name: {42 (ribociclib 200 MG Oral Tablet) } Pack


name: {42 (ribociclib 200 MG Oral Tablet [Kisqali]) } Pack [Kisqali 400 MG Daily Dose Carton]


name: {63 (ribociclib 200 MG Oral Tablet) } Pack


name: {63 (ribociclib 200 MG Oral Tablet [Kisqali]) } Pack [Kisqali 600 MG Daily Dose Carton]


name: Levetiracetam 24.75 kg in 25 kg NOT APPLICABLE POWDER [X]


name: MELOXICAM .99 kg in 1 kg NOT APPLICABLE POWDER [X]


name: OCTOCRYLENE 35 mg in 1 mL / OCTISALATE 50 mg in 1 mL / HOMOSALATE 80 mg in 1 mL / AVOBENZONE 27 mg in 1 mL / OXYBENZONE 40 mg in 1 mL TOPICAL LOTION [CVS Pharmacy SPF 30 Beach Guard Sun]


name: OCTOCRYLENE 45 mg in 1 mL / OCTISALATE 50 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / AVOBENZONE 30 mg in 1 mL / OXYBENZONE 40 mg in 1 mL TOPICAL LOTION [CVS Health SPF 70 Beach Guard Sun]


name: ZINC OXIDE 10 g in 100 mL / OCTINOXATE 7.5 g in 100 mL TOPICAL CREAM [Sunscreen Broad Spectrum SPF 50 Vi Aesthetics]


name: octinoxate 60 mg in 1 g / octisalate 50 mg in 1 g / oxybenzone 40 mg in 1 g / titanium dioxide 39 mg in 1 g / zinc oxide 20 mg in 1 g TOPICAL LOTION [Age Renewal Firming and Hydrating Moisturizer SPF 30]


name: Dimethicone;Triamcinolone Acetonide 5%; 0.1% Topical application Kit


name: 1,1,1,3,3-Pentafluoropropane/Norflurane;Dexamethasone Sodium Phosphate;Isopropyl Alcohol 10 MG/1 ML; 70% Multiple Routes Kit


name: Diphenhydramine Hydrochloride;Prednisone 50 MG; 50 MG Oral Kit


name: TheraNatal Lactation Complete, Prenatal Multivitamins with Folic Acid 0.4 mg oral kit


name: VSL#3 DS, oral powder for reconstitution


name: VSL#3 Junior, oral powder for reconstitution


name: VSL#3, Unflavored, oral powder for reconstitution


name: {1 (22 ML) (benzoyl peroxide 25 MG/ML Topical Lotion) / 1 (12 ML) (benzoyl peroxide 50 MG/ML Topical Lotion) / 1 (118 ML) (salicylic acid 20 MG/ML Medicated Liquid Soap) } Pack


name: WATER 1 mL in 1 mL INTRAVENOUS INJECTION [DILUENT]


name: OCTINOXATE 5678 mg in 75 mL / OCTOCRYLENE 2302 mg in 75 mL / TITANIUM DIOXIDE 1151 mg in 75 mL / ZINC OXIDE 14808 mg in 75 mL TOPICAL EMULSION [CLE DE PEAU BEAUTE UV PROTECTIVE VERY HIGH PROTECTION FOR BODY]


name: {7 (ethinyl estradiol 0.01 MG Oral Tablet) / 42 (ethinyl estradiol 0.02 MG / levonorgestrel 0.15 MG Oral Tablet) / 21 (ethinyl estradiol 0.025 MG / levonorgestrel 0.15 MG Oral Tablet) / 21 (ethinyl estradiol 0.03 MG / levonorgestrel 0.15 MG Oral Tablet) } Pack [Fayosim 91 Day]


name: OCTINOXATE 3870 mg in 50 mL / OCTOCRYLENE 1569 mg in 50 mL / ZINC OXIDE 8577 mg in 50 mL TOPICAL CREAM [CLE DE PEAU BEAUTE UV PROTECTIVE]


name: Penicillin G Potassium .99 kg in 1 kg NOT APPLICABLE POWDER [X]


name: OCTINOXATE 7 g in 100 mL / OXYBENZONE 5 g in 100 mL / OCTOCRYLENE 4 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL CREAM [NexGen Sunscreen Broad Spectrum SPF 36 Doc Martins]


name: OCTINOXATE 75 mg in 1 mL / OCTOCRYLENE 15 mg in 1 mL / OCTISALATE 50 mg in 1 mL / HOMOSALATE 90 mg in 1 mL / AVOBENZONE 20 mg in 1 mL / OXYBENZONE 50 mg in 1 mL TOPICAL LOTION [Fruit of the Earth Block Up SPF 50]


name: MELENGESTROL ACETATE 1 kg in 1 kg POWDER


name: GLYCERIN 8.6 g in 200 mL TOPICAL CREAM [NATURAL SAVON 4IN1 PLUS]


name: GLYCERIN 8.28 g in 180 mL TOPICAL LOTION [VITALISING TONIC]


name: GLYCERIN 1.97 g in 30 mL TOPICAL CREAM [NYMPHSYN INTENSIVE SERUM]


name: GLYCERIN 1.4 g in 50 mL TOPICAL CREAM [NYMPHSYN FACE MASK]


name: GLYCERIN 0.29 g in 30 mL TOPICAL CREAM [NYMPHSYN EYE]


name: maltodextrin/fructose 24 gram-100 kcal/27 gram ORAL POWDER IN PACKET (EA)


name: AVOBENZONE 1283 mg in 50 mL / OCTINOXATE 3796 mg in 50 mL / OCTOCRYLENE 1539 mg in 50 mL / OXYBENZONE 513 mg in 50 mL TOPICAL CREAM [SHISEIDO WHITE LUCENT ALL DAY BRIGHTENER N]


name: OCTINOXATE 138 mg in 4 mL / TITANIUM DIOXIDE 123 mg in 4 mL TOPICAL CREAM [SHISEIDO WHITE LUCENT ONMAKEUP SPOT CORRECTING SERUM NATURAL LIGHT]


name: OCTINOXATE 138 mg in 4 mL / TITANIUM DIOXIDE 123 mg in 4 mL TOPICAL CREAM [SHISEIDO WHITE LUCENT ONMAKEUP SPOT CORRECTING SERUM NATURAL]


name: OCTINOXATE 1655 mg in 30 mL / TITANIUM DIOXIDE 676 mg in 30 mL TOPICAL LIQUID [SHISEIDO SYNCHRO SKIN GLOW LUMINIZING FLUID FOUNDATION Golden 2]


name: OCTINOXATE 1655 mg in 30 mL / TITANIUM DIOXIDE 676 mg in 30 mL TOPICAL LIQUID [SHISEIDO SYNCHRO SKIN GLOW LUMINIZING FLUID FOUNDATION Golden 3]


name: OCTINOXATE 1655 mg in 30 mL / TITANIUM DIOXIDE 676 mg in 30 mL TOPICAL LIQUID [SHISEIDO SYNCHRO SKIN GLOW LUMINIZING FLUID FOUNDATION Golden 4]


name: OCTINOXATE 1655 mg in 30 mL / TITANIUM DIOXIDE 676 mg in 30 mL TOPICAL LIQUID [SHISEIDO SYNCHRO SKIN GLOW LUMINIZING FLUID FOUNDATION Golden 5]


name: OCTINOXATE 1655 mg in 30 mL / TITANIUM DIOXIDE 676 mg in 30 mL TOPICAL LIQUID [SHISEIDO SYNCHRO SKIN GLOW LUMINIZING FLUID FOUNDATION Neutral 1]


name: OCTINOXATE 1655 mg in 30 mL / TITANIUM DIOXIDE 676 mg in 30 mL TOPICAL LIQUID [SHISEIDO SYNCHRO SKIN GLOW LUMINIZING FLUID FOUNDATION Neutral 2]


name: OCTINOXATE 1655 mg in 30 mL / TITANIUM DIOXIDE 676 mg in 30 mL TOPICAL LIQUID [SHISEIDO SYNCHRO SKIN GLOW LUMINIZING FLUID FOUNDATION Neutral 3]


name: OCTINOXATE 1655 mg in 30 mL / TITANIUM DIOXIDE 676 mg in 30 mL TOPICAL LIQUID [SHISEIDO SYNCHRO SKIN GLOW LUMINIZING FLUID FOUNDATION Neutral 5]


name: OCTINOXATE 1655 mg in 30 mL / TITANIUM DIOXIDE 676 mg in 30 mL TOPICAL LIQUID [SHISEIDO SYNCHRO SKIN GLOW LUMINIZING FLUID FOUNDATION Rose 2]


name: OCTINOXATE 1655 mg in 30 mL / TITANIUM DIOXIDE 676 mg in 30 mL TOPICAL LIQUID [SHISEIDO SYNCHRO SKIN GLOW LUMINIZING FLUID FOUNDATION Rose 3]


name: OCTINOXATE 1655 mg in 30 mL / TITANIUM DIOXIDE 676 mg in 30 mL TOPICAL LIQUID [SHISEIDO SYNCHRO SKIN GLOW LUMINIZING FLUID FOUNDATION Rose 4]


name: OCTINOXATE 1655 mg in 30 mL / TITANIUM DIOXIDE 676 mg in 30 mL TOPICAL LIQUID [SHISEIDO SYNCHRO SKIN GLOW LUMINIZING FLUID FOUNDATION Rose 5]


name: OCTINOXATE 2449 mg in 30 mL / OCTOCRYLENE 993 mg in 30 mL / TITANIUM DIOXIDE 1522 mg in 30 mL TOPICAL CREAM [CLE DE PEAU BEAUTE UV PROTECTIVE TINTED DARK]


name: OCTINOXATE 2449 mg in 30 mL / OCTOCRYLENE 993 mg in 30 mL / TITANIUM DIOXIDE 1522 mg in 30 mL TOPICAL CREAM [CLE DE PEAU BEAUTE UV PROTECTIVE TINTED IVORY]


name: OCTINOXATE 2449 mg in 30 mL / OCTOCRYLENE 993 mg in 30 mL / TITANIUM DIOXIDE 1522 mg in 30 mL TOPICAL CREAM [CLE DE PEAU BEAUTE UV PROTECTIVE TINTED OCHER]


name: OCTINOXATE 306 mg in 9 g TOPICAL STICK [CLE DE PEAU BEAUTE RADIANT FOUNDATION BEIGE]


name: OCTINOXATE 306 mg in 9 g TOPICAL STICK [CLE DE PEAU BEAUTE RADIANT FOUNDATION IVORY]


name: OCTINOXATE 306 mg in 9 g TOPICAL STICK [CLE DE PEAU BEAUTE RADIANT FOUNDATION MOCHA]


name: OCTINOXATE 306 mg in 9 g TOPICAL STICK [CLE DE PEAU BEAUTE RADIANT FOUNDATION OCHER]


name: DIMETHICONE 7.06 g in 50 mL TOPICAL CREAM [OXY STEM M]


name: GLYCERIN 0.02 g in 2 mL TOPICAL LIQUID [G3S AMPOULE]


name: GLYCERIN 0.04 g in 5 mL TOPICAL LIQUID [ULTRA REJUVE 7S AMPOULE]


name: GLYCERIN 0.29 g in 5 mL TOPICAL LIQUID [PEPTICOL 5S AMPOULE]


name: GLYCERIN 2.04 g in 30 mL TOPICAL CREAM [RESURFACE MASK]


name: GLYCERIN 3.14 g in 50 mL TOPICAL CREAM [NYMPHSYN MAXIMIZER]


name: HYALURONIC ACID 0.15 g in 50 mL TOPICAL CREAM [HYALURON 3S SERUM]


name: SHEA BUTTER 2.4 g in 60 mL TOPICAL CREAM [ULTRA REPAIR]


name: WITCH HAZEL 3.0 g in 60 mL TOPICAL CREAM [HYDRA C3 TRIPLE RESET]


name: Titanium Dioxide 9.04 g in 45 g / Zinc Oxide 2.83 g in 45 g TOPICAL CREAM [SONATURAL POW DER4ROOM FIXING IT FULL COVER VANILLA BEIGE]


name: ADENOSINE 0.04 g in 100 mL TOPICAL LIQUID [DR. GLODERM TABRX WRINKLETOX MASK]


name: AMINO ACIDS, HAIR KERATIN 100 mg TOPICAL NOT APPLICABLE [keramatrix]


name: Dimethicone 0.06 g in 6 g TOPICAL POWDER [SONATURAL POW DER4ROOM MAKEUP HOLDING FINISH POW DER FIXER NATURAL YELLOW]


name: Dimethicone 0.12 g in 6 g TOPICAL POWDER [SONATURAL POW DER4ROOM MAKEUP HOLDING FINISH POW DER FIXER BRIGHT PINK]


name: Dimethicone 0.18 g in 1.5 g TOPICAL STICK [SONATURAL POW DER4ROOM SMUDGING ZERO REMOVER]


name: Dimethicone 1.5 g in 75 mL TOPICAL CREAM [SONATURAL HIGH WATER DRAW SUPER HYDRA BALM]


name: Dimethicone 5.0 g in 100 mL TOPICAL CREAM [SONATURAL FOR MEN STAY YOUNG ALL IN ONE FLUID]


name: GLYCERIN 1 g in 100 mL TOPICAL OIL [DR. GLODERM TABRX OILCAPSULE]


name: NIACINAMIDE 2 g in 100 mL TOPICAL LIQUID [DR. GLODERM TABRX WHITENING MASK]


name: Titanium Dioxide 9.04 g in 45 g / Zinc Oxide 2.83 g in 45 g TOPICAL CREAM [SONATURAL POW DER4ROOM FIXING IT FULL COVER NEUTRAL BEIGE]


name: AVOBENZONE 100 mg in 4 g / OCTINOXATE 196 mg in 4 g / OCTOCRYLENE 120 mg in 4 g / OXYBENZONE 80 mg in 4 g TOPICAL STICK [CLE DE PEAU BEAUTE UV PROTECTIVE LIP TREATMENT]


name: Titanium Dioxide 1.15 g in 12 g / Octinoxate 0.84 g in 12 g / Zinc Oxide 0.58 g in 12 g / Octisalate 0.54 g in 12 g TOPICAL POWDER [QUEENS ROSE PERFECTION COVER CUSHION PACT]


name: OCTINOXATE 2.75 g in 50 g / OCTISALATE 2.5 g in 50 g / ENSULIZOLE 2.0 g in 50 g / AVOBENZONE 1.5 g in 50 g TOPICAL CREAM [QUEENS ROSE WHOLE IN ONE SUNBLOCK]


name: Titanium Dioxide 6.69 g in 50 g / Zinc Oxide 0.72 g in 50 g TOPICAL CREAM [QUEENS ROSE ROSE SKIN PERFECTION BB]


name: Niacinamide 0.6 g in 30 mL / Adenosine 0.012 g in 30 mL TOPICAL CREAM [QUEENS ROSE RECOVERY EYE]


name: Niacinamide 1.2 g in 60 g / Adenosine 0.024 g in 60 g TOPICAL CREAM [QUEENS ROSE RECOVERY]


name: Niacinamide 2.2 g in 110 mL / Adenosine 0.044 g in 110 mL TOPICAL EMULSION [QUEENS ROSE RECOVERY]


name: Niacinamide 2.4 g in 120 mL / Adenosine 0.048 g in 120 mL TOPICAL LIQUID [QUEENS ROSE RECOVERY TONER]


name: Dimethicone 0.9 g in 45 mL TOPICAL LIQUID [QUEENS ROSE RECOVERY SERUM]


name: Dimethicone 1.25 g in 50 g TOPICAL CREAM [QUEENS ROSE ELYSEE ESSENCE EYE]


name: Dimethicone 5.41 g in 50 g TOPICAL CREAM [QUEENS ROSE ELYSEE]


name: Glycerin 0.19 g in 8 g TOPICAL LIQUID [QUEENS ROSE ELYSEE CONCEN TRATE DUAL AMPOULE]


name: Supervision of pregnancy with history of abortive outcome (treatment)


name: Extracorporeal High-Intensity Focused Ultrasound Therapy


name: Sum of Products of Perpendicular Diameters


name: {7 (ethinyl estradiol 0.01 MG Oral Tablet) / 84 (ethinyl estradiol 0.03 MG / levonorgestrel 0.15 MG Oral Tablet) } Pack [Simpesse 91 Day]


name: Amputation of finger of left hand (procedure)


name: Physical findings:Find:Pt:Teeth and gum:Nar:Observed


name: Alpha-Methylacyl Coenzyme A Racemase Measurement


name: Procedure used to obtain tumor specimen:Type:Pt:Specimen:Nom


name: Blood pressure panel with all children optional:-:Pt:Arterial system:Qn


name: Porcine epidemic diarrhea virus S INDEL strain S gene:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: Porcine epidemic diarrhea virus prototype & S INDEL strain S gene panel:-:Pt:XXX:-:Probe.amp.tar


name: Neutrophil.fMLP stimulated.DHR mean fluorescence intensity


name: Neutrophil.fMLP stimulated.DHR/Neutrophil.fMLP stimulated.total:NFr:Pt:Bld^Control:Qn:Flow cytometry


name: Neutrophil.PMA stimulated.DHR mean fluorescence intensity:Arb:Pt:Bld:Qn:Flow cytometry


name: Did your heart failure prevent you from living as you wanted during the past Mo (4W) by causing swelling in your ankles or legs


name: Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making your working around the house or yard difficult


name: Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making your relating to or doing things with your friends or family difficult:Find:1Mo:^Patient:Ord:MLHFQ


name: LCDS v3.00 - Mobility - discharge performance during 3D assessment period:-:3D:^Patient:-:CMS Assessment


name: Date of serology test^pre pregnancy:Date:Pt:^Mother:Qn


name: Neisseria meningitidis DNA:PrThr:Pt:Bld.pos growth:Ord:Non-probe.amp.tar


name: Streptococcus pneumoniae Danish serotype 19F Ab.IgG^2nd specimen/1st specimen:Ratio:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 19F Ab^1st specimen:MCnc:Pt:Ser:Qn


name: Views for bone density:ArMass:Pt:Upper extremity>Humerus:Qn:DXA


name: Views for bone density:ArMass:Pt:Upper extremity.right>Humerus:Qn:DXA


name: Views for bone density:Tscore:Pt:Upper extremity.left>Humerus:Qn:DXA


name: IRF-PAI - Medical information:-:RptPeriod:^Patient:-:CMS Assessment


name: IRF-PAI - Impairment group - discharge:-:RptPeriod:^Patient:-:CMS Assessment


name: Program return date:Date:RptPeriod:^Patient:Qn:CMS Assessment


name: Diagnosis for interruption or death:Find:RptPeriod:^Patient:Nom:CMS Assessment


name: Does the patient walk - discharge performance during 3D assessment period


name: Inpatient Rehabilitation Facility - Patient Assessment Instrument - version 1.4


name: IRF-PAI - Functional abilities and goals - admission


name: Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Unplanned Discharge - version 3.00


name: Send document that conforms to Level 3 EMS R1 template


name: Send document that conforms to Level 3 EMS R1 template:Scope.modifier.doc template:Pt:X12^277:-


name: Cardiac implantable loop monitor study:Find:Stdy:Heart:Doc


name: Congenital rubella syndrome case classification:Imp:Pt:^Patient:Nom


name: Congenital rubella syndrome case classification


name: PROMIS short form - global - version 1.2 raw score:Score:Pt:^Patient:Qn:PROMIS


name: PROMIS short form - global - version 1.2 raw score


name: Salivary gland swelling duration:Time:Pt:^Patient:Qn


name: Note:Find:Pt:{Setting}:Doc:Maternal and fetal medicine


name: Health and well-being total:Score:Pt:^Patient:Qn:ePCAM


name: Lifestyle behaviors impacting physical or mental well-being - visual analog rating:Score:Pt:^Patient:Qn:ePCAM


name: Daily activities impact on well-being - visual analog rating:Score:Pt:^Patient:Qn:ePCAM


name: Influenza virus A & B & Respiratory syncytial virus RNA panel:-:Pt:Respiratory system specimen.upper:-:Probe.amp.tar


name: Influenza virus B RNA:PrThr:Pt:Respiratory system specimen.upper:Ord:Probe.amp.tar


name: Establishment registration exempt notification:-:-:^FDA product label:Nar


name: IRF-PAI - Therapy provided - week 2:-:RptPeriod:^Patient:-:CMS Assessment


name: Bacterial carbapenem resistance blaKPC gene:PrThr:Pt:Anorectal/isolate:Ord:Probe.amp.tar


name: PIK3CA gene targeted mutation analysis:Prid:Pt:Colorectal cancer specimen:Nom:Molgen


name: KRAS gene targeted mutation analysis:Prid:Pt:Colorectal cancer specimen:Nom:Molgen


name: Consultation note:Find:Pt:{Setting}:Doc:Child and adolescent psychology


name: Note:Find:Pt:{Setting}:Doc:Undersea and hyperbaric medicine


name: Mycoplasma hyopneumoniae P146 gene sequence & phylogenetic analysis:Find:Pt:XXX:Doc


name: Porcine reproductive and respiratory syndrome virus European strain Ab.IgG:Titr:Pt:Ser:SemiQn:IF


name: Porcine reproductive and respiratory syndrome virus European strain Ab.IgG:PrThr:Pt:Ser:Ord:IF


name: Porcine reproductive and respiratory syndrome virus Ab.IgG/Positive control:RelRto:Pt:Saliva:Qn:IA


name: Porcine reproductive and respiratory syndrome virus European strain Ab.Neut:PrThr:Pt:Ser:Ord:Neut


name: Porcine reproductive and respiratory syndrome virus European & North American strains Ab.Neut panel:-:Pt:Ser:-:Neut


name: Influenza virus A porcine origin nucleoprotein Ab.IgA/Positive control:RelRto:Pt:XXX:Qn:IA


name: Physical therapy - co-treatment minutes^week 1:Time:RptPeriod:^Patient:Qn:CMS Assessment


name: Occupational therapy - individual minutes^week 1:Time:RptPeriod:^Patient:Qn:CMS Assessment


name: Occupational therapy - group minutes^week 1:Time:RptPeriod:^Patient:Qn:CMS Assessment


name: Occupational Therapy - co-treatment minutes^week 2:Time:RptPeriod:^Patient:Qn:CMS Assessment


name: Special treatments, procedures, and programs - discharge


name: Speech-language pathology services - group minutes


name: Title of person collecting or coordinating collection of assessment information


name: Against medical advice note:Find:Pt:{Setting}:Doc:{Role}


name: Chemokine (C-C Motif) Ligand 19 Measurement


name: {2 (0.4 ML adalimumab 100 MG/ML Auto-Injector [Humira]) / 1 (0.8 ML adalimumab 100 MG/ML Auto-Injector [Humira]) } Pack [Humira Pen 80 MG/0.8 ML and 40 MG/0.4 ML - Psoriasis/Uveitis Starter Package]


name: {3 (0.8 ML adalimumab 100 MG/ML Auto-Injector [Humira]) } Pack [Humira Pen 80 MG/0.8 ML - Starter Package for Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa]


name: {28 (letrozole 2.5 MG Oral Tablet [Femara]) / 21 (ribociclib 200 MG Oral Tablet [Kisqali]) } Pack [Kisqali Femara Co-Pack 200]


name: {28 (letrozole 2.5 MG Oral Tablet [Femara]) / 63 (ribociclib 200 MG Oral Tablet [Kisqali]) } Pack [Kisqali Femara Co-Pack 600]


name: {28 (letrozole 2.5 MG Oral Tablet [Femara]) / 42 (ribociclib 200 MG Oral Tablet [Kisqali]) } Pack [Kisqali Femara Co-Pack 400]


name: Speech-language pathology services - concurrent minutes^week 2:Time:RptPeriod:^Patient:Qn:CMS Assessment


name: Porcine reproductive and respiratory syndrome virus European strain ORF5 gene:PrThr:Pt:XXX:Ord:Probe.amp.tar


name: Porcine reproductive and respiratory syndrome virus European & North American strains Ab.IgG panel:-:Pt:Ser:-:IF


name: Preferred type of dialysis if required before transplant:Type:Pt:^Patient:Nom


name: Renal replacement therapy goals panel:-:Pt:^Patient:-:NKDEP


name: Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making you stay in a hospital:Find:1Mo:^Patient:Ord:MLHFQ


name: Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making it difficult for you to concentrate or remember things:Find:1Mo:^Patient:Ord:MLHFQ


name: Kidney failure 5Y risk:Likelihood:Pt:^Patient:Qn:KFRE


name: Haemophilus influenzae hpd gene:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: LCDS v3.00 - Functional abilities and goals


name: Signature of person collecting or coordinating collection of assessment information:Pn:Pt:Provider:Nar


name: LCDS v3.00 - Signs and Symptoms of Delirium (from CAM):-:3D:^Patient:-:CMS Assessment


name: Was the patient's thinking disorganized or incoherent, such as rambling or irrelevant conversation, unclear or illogical flow of ideas, or unpredictable switching from subject to subject during 3D assessment period:Find:3D:^Patient:Ord:CAM.CMS


name: Occupation CDC Census code:Type:Pt:^Patient:Nom


name: LCDS v3.00 - Self-care - discharge goal:-:3D:^Patient:-:CMS Assessment


name: Haemophilus influenzae bex gene:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: Haemophilus influenzae ecs gene:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: Sexual activity with known Chlamydia trachomatis &or Neisseria gonorhoeae case:PrThr:Pt:^Patient:Ord


name: Previous rubella disease was serologically confirmed:Find:Pt:^Patient:Ord


name: Age at time of immunity testing:Time:Pt:^Patient:Qn


name: Has had previous deliveries in the U.S.:Find:Pt:^Mother:Ord


name: Gestational age in W^at cessation of pregnancy:Time:Pt:^Fetus:Qn


name: Non-agency caregiver ability and willingness to assist with advocacy or facilitation of patient participation


name: Rubella vaccine was received by children under the age of 18 in the household during the pregnancy:Find:Pt:^Mother:Ord


name: Streptococcus pneumoniae Danish serotype 4 DNA:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: Streptococcus pneumoniae Danish serotype 14 DNA:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: Streptococcus pneumoniae Danish serotypes 6A+6B+6C+6D DNA:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: Streptococcus pneumoniae Danish serotypes 33A+33F+37 DNA:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: Staphylococcus aureus DNA:PrThr:Pt:Bld.pos growth:Ord:Non-probe.amp.tar


name: Streptococcus agalactiae DNA:PrThr:Pt:Bld.pos growth:Ord:Non-probe.amp.tar


name: Klebsiella oxytoca DNA:PrThr:Pt:Bld.pos growth:Ord:Non-probe.amp.tar


name: Proteus sp DNA:PrThr:Pt:Bld.pos growth:Ord:Non-probe.amp.tar


name: Serratia marcescens DNA:PrThr:Pt:Bld.pos growth:Ord:Non-probe.amp.tar


name: Bacterial carbapenem resistance blaKPC gene:PrThr:Pt:Bld.pos growth:Ord:Non-probe.amp.tar


name: Neisseria meningitidis serogroup DNA panel:-:Pt:XXX:-:Probe.amp.tar


name: Measles virus N gene:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: Mumps virus SH gene:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: Mumps virus RNA & SH gene panel:-:Pt:XXX:-:Probe.amp.tar


name: LCDS v4.00 - Patient demographic information - admission


name: Bacterial carbapenem resistance blaIMP gene:PrThr:Pt:Isolate:Ord:Probe.amp.tar


name: Bacterial carbapenem resistance blaOXA-24-like gene:PrThr:Pt:Isolate/Specimen:Ord:Molgen


name: Bacterial carbapenem resistance blaOXA-58-like gene:PrThr:Pt:Isolate/Specimen:Ord:Molgen


name: Bacterial beta-lactam resistance ESBL blaCTX-M-9 group gene:PrThr:Pt:Isolate/Specimen:Ord:Molgen


name: Bacterial beta-lactam resistance ESBL blaCTX-M-8+blaCTX-M-25 group genes:PrThr:Pt:Isolate/Specimen:Ord:Molgen


name: Bacterial beta-lactam resistance ESBL blaPER gene:PrThr:Pt:Isolate/Specimen:Ord:Molgen


name: History and physical note:Find:Pt:{Setting}:Doc:Thoracic and cardiac surgery


name: Chemokine (C-C Motif) Ligand 7 Measurement


name: Note:Find:Pt:{Setting}:Doc:Thoracic and cardiac surgery.nurse


name: History and physical note:Find:Pt:Outpatient:Doc:Womens health


name: Group counseling note:Find:Pt:{Setting}:Doc:Womens health


name: Consultation note:Find:Pt:{Setting}:Doc:Community health care


name: Date of salivary gland swelling onset:Date:Pt:^Patient:Qn


name: Postoperative evaluation and management note:Find:Pt:{Setting}:Doc:Clinical cardiac electrophysiology


name: Preoperative evaluation and management note:Find:Pt:{Setting}:Doc:Gastroenterology


name: Preoperative evaluation and management note:Find:Pt:{Setting}:Doc:Pulmonary disease


name: Streptococcus pneumoniae Danish serotype 1 Ab.IgG:MCnc:Pt:Ser:Qn


name: Retinal nerve fiber layer.clock hour 4 thickness:Len:Pt:Retina.right:Qn:OCT


name: Retinal nerve fiber layer.clock hour 9 thickness


name: Retinal nerve fiber layer.clock hour 11 thickness:Len:Pt:Retina.right:Qn:OCT


name: Bacterial methicillin resistance mecA+mecC genes:PrThr:Pt:Nose:Ord:Probe.amp.tar


name: Bacterial methicillin resistance mecC gene:PrThr:Pt:Isolate/Specimen:Ord:Molgen


name: Send document that conforms to Level 3 EMS R2 template:Scope.modifier.doc template:Pt:X12^277:-


name: Streptococcus pneumoniae Danish serotype 1 Ab.IgG^1st specimen:ACnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 1 Ab.IgG^2nd specimen:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 1 Ab.IgG^2nd specimen/1st specimen:Ratio:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 12F Ab:PrThr:Pt:Ser:Ord


name: Streptococcus pneumoniae Danish serotype 12F Ab.IgG^1st specimen:ACnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 12F Ab^2nd specimen:ACnc:Pt:Ser:Qn


name: How much time did you usually spend doing vigorous physical activities on one of those D


name: How much time did you usually spend doing moderate physical activities on one of those D


name: How much time did you usually spend walking on one of those D


name: Streptococcus pneumoniae Danish serotype 12F Ab^2nd specimen/1st specimen:Ratio:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 14 Ab:ACnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 14 Ab.IgG^1st specimen:ACnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 14 Ab.IgG^2nd specimen:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 14 Ab^1st specimen:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 14 Ab^2nd specimen/1st specimen:Ratio:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 17F Ab.IgG^1st specimen:MCnc:Pt:Ser:Qn:IA


name: Streptococcus pneumoniae Danish serotype 18F Ab^1st specimen:ACnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 19F Ab:ACnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 19F Ab.IgG:MCnc:Pt:Ser:Qn:IA


name: Streptococcus pneumoniae Danish serotype 19F Ab.IgG^2nd specimen:ACnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 19F Ab^2nd specimen:ACnc:Pt:Ser:Qn:IA


name: Streptococcus pneumoniae Danish serotype 19F Ab^2nd specimen:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 2 Ab.IgG^2nd specimen/1st specimen:Ratio:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 20A Ab.IgG:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 20A Ab.IgG^1st specimen:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 22F Ab.IgG^1st specimen:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 22F Ab.IgG^2nd specimen:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 22F Ab.IgG^2nd specimen/1st specimen:Ratio:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 23F Ab.IgG:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 23F Ab.IgG^1st specimen:ACnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 23F Ab.IgG^2nd specimen:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 23F Ab^2nd specimen:ACnc:Pt:Ser:Qn:IA


name: Streptococcus pneumoniae Danish serotype 23F Ab^2nd specimen:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 3 Ab:ACnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 3 Ab.IgG^1st specimen:ACnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 3 Ab.IgG^2nd specimen:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 3 Ab.IgG^2nd specimen/1st specimen:Ratio:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 3 Ab^2nd specimen/1st specimen:Ratio:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 10A Ab.IgG^1st specimen:MCnc:Pt:Ser:Qn:IA


name: Streptococcus pneumoniae Danish serotype 4 Ab.IgG:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 4 Ab.IgG:MCnc:Pt:Ser:Qn:IA


name: Streptococcus pneumoniae Danish serotype 4 Ab.IgG:ACnc:Pt:Ser:Qn:IA


name: Views diagnostic for technical call back:Find:Pt:Breast:Doc:MG


name: Actinobacillus pleuropneumoniae serotype 3 Ab:Titr:Pt:Ser:SemiQn:Comp fix


name: Streptococcus pneumoniae Danish serotype 4 Ab.IgG^1st specimen:ACnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 4 Ab^2nd specimen:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 11A Ab.IgG:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 11A Ab.IgG^1st specimen:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 5 Ab.IgG:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 5 Ab.IgG^1st specimen:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 5 Ab.IgG^2nd specimen:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 8 Ab.IgG:ACnc:Pt:Ser:Qn:IA


name: Streptococcus pneumoniae Danish serotype 8 Ab.IgG^1st specimen:MCnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 8 Ab.IgG^2nd specimen:MCnc:Pt:Ser:Qn:IA


name: Streptococcus pneumoniae Danish serotype 8 Ab^2nd specimen:ACnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 9N Ab:ACnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 9N Ab:PrThr:Pt:Ser:Ord


name: Streptococcus pneumoniae Danish serotype 9N Ab.IgG^1st specimen:MCnc:Pt:Ser:Qn:IA


name: Streptococcus pneumoniae Danish serotype 9N Ab.IgG^2nd specimen:ACnc:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 9N Ab.IgG^2nd specimen/1st specimen:Ratio:Pt:Ser:Qn


name: Streptococcus pneumoniae Danish serotype 9N Ab^2nd specimen:ACnc:Pt:Ser:Qn


name: Neisseria meningitidis serogroup Y synF gene:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: Degree of difficulty experienced due to your hip while bending to floor &or pick up an object in the last W:Find:1W:^Patient:Ord:HOOS


name: Degree of difficulty experienced due to your hip while sitting in the last W


name: Porcine epidemic diarrhea virus:PrThr:Pt:XXX:Ord:Organism specific culture


name: Porcine epidemic diarrhea virus Ab.IgG:PrThr:Pt:Ser:Ord:IF


name: Note:Find:Pt:{Setting}:Doc:Community health care.case manager


name: Retinal nerve fiber layer.nasal thickness:Len:Pt:Retina.right:Qn:OCT


name: Diagnostic mammogram & ultrasound panel:Find:Pt:Breast.left:Doc


name: Guidance for needle localization:Find:Pt:Breast.left:Doc:MG


name: Diagnostic mammogram & ultrasound panel:Find:Pt:Breast.right:Doc


name: Sexual activity in the last Y:Find:1Y:^Patient:Ord:Reported


name: Reason for no birth control use^at intake:Find:Pt:^Patient:Nom:Reported


name: Rotavirus A VP6 capsid protein:PrThr:Pt:XXX:Ord:IA


name: Porcine epidemic diarrhea virus Ab.IgG:Titr:Pt:Ser:SemiQn:IF


name: Bacterial colistin resistance mcr-1 gene:PrThr:Pt:Isolate/Specimen:Ord:Molgen


name: Neisseria meningitidis serogroup A sacB gene:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: Neisseria meningitidis serogroup C synE gene:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: Retinal nerve fiber layer.temporal thickness:Len:Pt:Retina.right:Qn:OCT


name: Retinal nerve fiber layer.temporal superior thickness:Len:Pt:Retina.left:Qn:OCT


name: Retinal nerve fiber layer.inferior temporal thickness:Len:Pt:Retina.right:Qn:OCT


name: Retinal nerve fiber layer.inferior thickness:Len:Pt:Retina.left:Qn:OCT


name: Retinal nerve fiber layer.mean thickness:Len:Pt:Retina.left:Qn:OCT


name: Retinal nerve fiber layer.clock hour 4 thickness:Len:Pt:Retina.left:Qn:OCT


name: Retinal nerve fiber layer.clock hour 6 thickness:Len:Pt:Retina.left:Qn:OCT


name: Retinal nerve fiber layer.clock hour 8 thickness:Len:Pt:Retina.left:Qn:OCT


name: Retinal nerve fiber layer.clock hour 3 thickness:Len:Pt:Retina.right:Qn:OCT


name: Influenza virus A H1 2009 pandemic RNA:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: Bordetella pertussis+parapertussis ptxS1 gene:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: Bordetella parapertussis IS1001 DNA:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: Vascular Endothelial Growth Factor A Measurement


name: 1 step (curb) - functional goal recorded during 3D assessment period:Find:3D:^Patient:Ord:CMS Assessment


name: Walk 150 feet - functional goal recorded during 3D assessment period:Find:3D:^Patient:Ord:CMS Assessment


name: Car transfer - functional ability during 3D assessment period:Find:3D:^Patient:Ord:CMS Assessment


name: Toilet transfer - functional ability during 3D assessment period:Find:3D:^Patient:Ord:CMS Assessment


name: Bed-to-chair transfer - functional ability during 3D assessment period:Find:3D:^Patient:Ord:CMS Assessment


name: Roll left and right - functional goal recorded during 3D assessment period:Find:3D:^Patient:Ord:CMS Assessment


name: Putting on and taking off footwear - functional goal recorded during 3D assessment period:Find:3D:^Patient:Ord:CMS Assessment


name: Total interval score change:ScoreDiff:Pt:^Patient:Qn:HOOSJR


name: Streptococcus pneumoniae Danish serotype 6A+6B Ab:MCnc:Pt:Ser:Qn


name: U.S. standard certificate of death - recommended 2003 revision set:-:Pt:{Setting}:-


name: U.S. standard certificate of live birth - recommended 2003 revision set:-:Pt:{Setting}:-


name: Views diagnostic for clinical call back:Find:Pt:Breast.left:Doc:MG


name: Guidance for advancement of feeding tube:Find:Pt:Abdomen+Pelvis>Gastrointestinal tract:Doc:RF


name: Views^post fatty meal+W contrast PO:Find:Pt:Abdomen>Gallbladder:Doc:RF


name: Views^W barium contrast PO:Find:Pt:Abdomen>Gastrointestinal tract.upper:Doc:RF


name: Views^W contrast retrograde:Find:Pt:Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder:Doc:RF


name: Views & Guidance for injection of non-vascular shunt:Find:Pt:XXX:Doc:RF


name: Views^W contrast intra bladder:Find:Pt:Pelvis>Urinary bladder:Doc:RF


name: Guidance for placement of catheter:Find:Pt:Pelvis>Fallopian tube:Doc:RF


name: Views for rectal dysfunction^W barium contrast PR:Find:Pt:Pelvis>Rectum:Doc:RF


name: Views^W contrast IT:Find:Pt:Head>Posterior fossa.bilateral:Doc:RF


name: Views^W contrast intra lymphatic:Find:Pt:Lower extremity>Pedal lymphatic vessels:Doc:RF.angio


name: Views^W contrast IA:Find:Pt:Chest>Pulmonary arteries.unilateral:Doc:RF.angio


name: Views^W air contrast PO+W barium contrast PO:Find:Pt:Abdomen>Gastrointestinal tract.upper:Doc:RF


name: View && Views^W water soluble contrast PO:Find:Pt:Abdomen>Gastrointestinal tract.upper:Doc:XR && RF


name: Views^W contrast IA:Find:Pt:Extremity.unilateral>Extremity arteries:Doc:RF.angio


name: Views^W contrast IT:Find:Pt:Head>Posterior fossa.unilateral:Doc:RF


name: Views diagnostic^W contrast intra fistula:Find:Pt:XXX>Fistula:Doc:RF


name: Views^W contrast IV:Find:Pt:Head>Cerebral sinuses:Doc:RF


name: Guidance for manometry:Find:Pt:Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder:Doc:RF


name: Human cell and tissue establishment registration & product listing change in information:-:-:^FDA product label:Nar


name: Human salvaged drug:-:-:^FDA product label:Nar


name: Preoperative evaluation and management note:Find:Pt:{Setting}:Doc:Radiology


name: Lower body dressing - functional goal recorded during 3D assessment period:Find:3D:^Patient:Ord:CMS Assessment


name: Bowel continence during 3D assessment period:Find:3D:^Patient:Ord:CMS Assessment


name: IRF-PAI v2.0 - Swallowing &or nutritional status - admission:-:3D:^Patient:-:CMS Assessment


name: IRF-PAI - Hearing, speech, and vision - admission


name: IRF-PAI - Mobility - admission performance during 3D assessment period:-:3D:^Patient:-:CMS Assessment


name: Does the patient use a wheelchair or scooter during 3D assessment period:Find:3D:^Patient:Ord:CMS Assessment


name: Indicate the type of wheelchair or scooter used during 3D assessment period


name: Has the patient had any falls since admission:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Worsening in pressure injury status since admission:-:RptPeriod:^Patient:-:CMS Assessment


name: Stage 3 pressure injuries not present or at a lesser stage on admission &or reentry:Num:RptPeriod:^Patient:Qn:CMS Assessment


name: Body structure included in specimen:Anat:Pt:Specimen:Nom


name: Serine-threonine protein kinase B-raf V600E


name: Views for bone density:Tscore:Pt:Upper extremity>Humerus:Qn:DXA


name: Mycoplasma hyosynoviae 16S rRNA gene:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: Did your heart failure prevent you from living as you wanted during the past Mo (4W) by costing you money for medical care:Find:1Mo:^Patient:Ord:MLHFQ


name: Vaccinated based on recommended guidelines:Find:Pt:^Patient:Ord


name: Mo of pregnancy when rubella-like symptoms appeared:Date:Pt:^Mother:Qn


name: Climbing a flight of stairs without stopping was limited by heart failure over the past 2W:Find:2W:^Patient:Ord:KCCQ


name: Change in symptoms of heart failure compared with 2W ago:Find:Pt:^Patient:Ord:KCCQ


name: Sleep sitting up in a chair or with at least 3 pillows to prop you up because of shortness of breath over the past 2W:Find:2W:^Patient:Ord:KCCQ


name: Understand what things you are able to do to keep your heart failure symptoms from getting worse:Find:Pt:^Patient:Ord:KCCQ


name: How would you feel if you had to spend the rest of your life with your heart failure the way it is right now:Find:Pt:^Patient:Ord:KCCQ


name: Herpes simplex virus DNA:PrThr:Pt:Tiss:Ord:Probe.amp.tar


name: Herpes virus 7 DNA:PrThr:Pt:Bld:Ord:Probe.amp.tar


name: Herpes virus 8 DNA:PrThr:Pt:Bld:Ord:Probe.amp.tar


name: Staff who worked at facility at least one day from October 1 through March 31


name: Staff who provided documentation of influenza vaccine receipt


name: Human papilloma virus DNA:PrThr:Pt:Tiss:Ord:Probe.amp.tar


name: Influenza virus A Ag:PrThr:Pt:Tiss:Ord:IF


name: Influenza virus A Ab.IgM:PrThr:Pt:Ser:Ord:IA


name: Varicella zoster virus Ag:PrThr:Pt:Tiss:Ord:IF


name: Function and daily living panel:-:1W:^Patient:-:KOOSJR


name: Family planning report - FPAR 2.0 set:-:Pt:^Patient:-


name: Information source for pregnancy status:Type:Pt:^Patient:Nom


name: Pregnancy intention in the next Y:Find:Pt:^Patient:Nom:Reported


name: Views for bone density:Zscore:Pt:Upper extremity>Humerus:Qn:DXA


name: Views for bone density:Zscore:Pt:Upper extremity.left>Humerus:Qn:DXA


name: Blood pathogens panel:-:Pt:Bld.pos growth:-:Non-probe.amp.tar


name: Staphylococcus sp DNA:PrThr:Pt:Bld.pos growth:Ord:Non-probe.amp.tar


name: Self-care - discharge goal:-:3D:^Patient:-:CMS Assessment


name: Mobility - discharge goal during 3D assessment period:-:3D:^Patient:-:CMS Assessment


name: Prior functioning.indoor mobility-ambulation:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Distance of carcinoma from closest surgical margin when all margins are uninvolved:Len:Pt:Cancer specimen:Qn:Microscopy.light


name: Intratumoral lymphocytic response:Find:Pt:Cancer specimen:Ord:Microscopy.light


name: Radial position of closest mucosal margin involved by invasive carcinoma:Angle:Pt:Colorectal cancer specimen:Qn:Microscopy.light


name: Radial position of closest mucosal margin when mucosal margin uninvolved by invasive carcinoma:Angle:Pt:Colorectal cancer specimen:Qn:Microscopy.light


name: Surgical margin tumor involvement:PrThr:Pt:Colorectal cancer specimen:Ord:Microscopy.light


name: Growth pattern of DCIS:Type:Pt:Breast cancer specimen:Nom:Microscopy.light


name: Distance of carcinoma from uninvolved inferior margin:Len:Pt:Breast cancer specimen:Qn:Microscopy.light


name: Extent of anterior margin carcinoma involvement:Find:Pt:Breast cancer specimen:Ord:Microscopy.light


name: Extent of inferior margin carcinoma involvement:Find:Pt:Breast cancer specimen:Ord:Microscopy.light


name: Extent of medial margin carcinoma involvement:Find:Pt:Breast cancer specimen:Ord:Microscopy.light


name: Cells.progesterone receptor/100 cells:NFr:Pt:Breast cancer specimen:Qn:Immune stain


name: Cells.estrogen receptor/100 cells:NFr:Pt:Breast cancer specimen:Qn:Immune stain


name: DCIS.additional dimension 2:Len:Pt:Breast cancer specimen:Qn:Microscopy.light


name: Estrogen receptor Ag:PrThr:Pt:Breast cancer specimen:Ord:Immune stain


name: HPV tests - FPAR 2.0 set:-:Pt:^Patient:-


name: Neisseria gonorrhoeae tests - FPAR 2.0 set:-:Pt:^Patient:-


name: Level of tumor invasion:Find:Pt:Skin melanoma:Ord:Clark


name: Porcine epidemic diarrhea virus Ab/Positive control:RelRto:Pt:Ser:Qn:IA


name: Porcine epidemic diarrhea virus RNA:NCnc:Pt:XXX:Qn:Probe.amp.tar


name: Cause of death classification+related information:Find:Pt:^Patient:Doc


name: Dengue virus 1 Ab.Neut:Titr:Pt:XXX:SemiQn:Neut


name: {16 (acetaminophen 325 MG / dextromethorphan hydrobromide 10 MG / doxylamine succinate 6.25 MG / phenylephrine hydrochloride 5 MG Oral Capsule) / 24 (acetaminophen 325 MG / dextromethorphan hydrobromide 10 MG / phenylephrine hydrochloride 5 MG Oral Capsule) } Pack


name: Amputation of finger of right hand (procedure)


name: Attribute cardinality (foundation metadata concept)


name: Minnesota Living with Heart Failure Questionnaire (MLHFQ)


name: Interleukin-4 Receptor alpha Antagonist [EPC]


name: {7 (ethinyl estradiol 0.01 MG Oral Tablet) / 84 (ethinyl estradiol 0.02 MG / levonorgestrel 0.1 MG Oral Tablet) } Pack [Lo Simpesse 91 Day]


name: {28 (letrozole 2.5 MG Oral Tablet) / 21 (ribociclib 200 MG Oral Tablet) } Pack


name: {28 (letrozole 2.5 MG Oral Tablet) / 42 (ribociclib 200 MG Oral Tablet) } Pack


name: {28 (letrozole 2.5 MG Oral Tablet) / 63 (ribociclib 200 MG Oral Tablet) } Pack


name: {21 (desogestrel 0.15 MG / ethinyl estradiol 0.03 MG Oral Tablet) / 7 (inert ingredients 1 MG Oral Tablet) } Pack [Kalliga 28 Day]


name: CDISC SDTM Specimen Collection Method Terminology


name: Exposure to intestinal infectious disease (event)


name: Healthcare associated infection report - recommended CDA R3 set


name: Healthcare associated infection report - recommended CDA R3 set:-:Pt:{Setting}:-


name: Periodontal attachment - recommended CDA R1 set


name: Periodontal attachment - recommended CDA R1 set:-:Pt:{Setting}:-


name: Send document that conforms to Oncology Treatment Plan Summary R1.2 template


name: Send document that conforms to Oncology Treatment Plan Summary R1.2 template:Scope.modifier.doc template:Pt:X12^277:-


name: Neisseria gonorrhoeae tests - FPAR 2.0 set


name: Jurisdiction death information - recommended CDA R1 sections


name: Jurisdiction death information - recommended CDA R1 sections:-:Pt:{Setting}:-


name: Male sexual partner in last 12Mo:PrThr:Pt:^Patient:Ord


name: PROMIS short form - global - version 1.2:-:Pt:^Patient:-:PROMIS


name: PROMIS short form - global - version 1.2


name: Send document that conforms to Oncology Treatment Plan Summary R1.2.1 template:Scope.modifier.doc template:Pt:X12^277:-


name: Send document that conforms to Oncology Treatment Plan Summary R1.2.1 template


name: Amputation of left forearm through radius and ulna


name: Substance with thymidine phosphorylase inhibitor mechanism of action (substance)


name: Substance with peroxisome proliferator-activated gamma receptor agonist mechanism of action (substance)


name: Vesicular monoamine transporter 2 inhibitor


name: Substance with polyadenosine 5'-diphosphoribose polymerase inhibitor mechanism of action (substance)


name: Content type (foundation metadata concept)


name: Serine-threonine protein kinase B-raf V600E:PrThr:Pt:Cancer specimen:Ord:Immune stain


name: Home (private home/apt., board/care, assisted living, group home, transistional living)


name: International Physical Activity Questionnaire (IPAQ)


name: Percent Change From Nadir in Sum of Products of Perpendicular Diameters


name: International Physical Activity Questionnaire (IPAQ) set


name: Usually Need Help from Another Person for Walking


name: Hydrolytic Lysosomal N-terminal Tripeptidyl Peptidase [EPC]


name: Counseling to achieve pregnancy was provided


name: Counseling to achieve pregnancy was provided:Find:Pt:^Patient:Ord


name: Occupation industry CDC Census code:Type:Pt:^Patient:Nom


name: Previous rubella virus test result:Find:Pt:^Patient:Nom


name: Send document that conforms to Oncology Treatment Plan Summary R1.3 template:Scope.modifier.doc template:Pt:X12^277:-


name: Send document that conforms to Oncology Treatment Plan Summary R1.3 template


name: {1 (diphenhydramine hydrochloride 25 MG / phenylephrine hydrochloride 10 MG Oral Tablet) / 1 (phenylephrine hydrochloride 10 MG Oral Tablet) } Pack


name: {21 (ethinyl estradiol 0.02 MG / norethindrone acetate 1 MG Oral Tablet) / 7 (ferrous fumarate 75 MG Oral Tablet) } Pack [Aurovela Fe 1/20 28 Day]


name: {21 (ethinyl estradiol 0.02 MG / norethindrone acetate 1 MG Oral Tablet) } Pack [Aurovela 1/20 21 Day]


name: {24 (ethinyl estradiol 0.02 MG / norethindrone acetate 1 MG Oral Tablet) / 4 (ferrous fumarate 75 MG Oral Tablet) } Pack [Aurovela Fe 24 1/20 28 Day]


name: {21 (ethinyl estradiol 0.03 MG / norethindrone acetate 1.5 MG Oral Tablet) } Pack [Aurovela 1.5/30 21 Day]


name: Healthcare associated infection report - recommended CDA R2 sections


name: U.S. standard certificate of death - recommended 2003 revision set


name: U.S. standard report of fetal death - recommended 2003 revision set


name: U.S. standard report of fetal death - recommended 2003 revision set:-:Pt:{Setting}:-


name: How birth control method was provided:Find:Pt:^Patient:Nom


name: Relational and Item-Specific Encoding Task


name: Contraceptive counseling was provided:Find:Pt:^Patient:Ord


name: Age and setting of exposure to illness verified:Find:Pt:^Patient:Ord


name: Congenital rubella case report panel:-:Pt:^Patient:-


name: Date of condition onset:Date:Pt:^Patient:Qn


name: Minnesota Living with Heart Failure Questionnaire (MLHFQ) set


name: Streptococcus pneumoniae Danish serotype 7A Ab.IgG:ACnc:Pt:Ser:Qn:IA


name: Electronic Patient Centered Assessment Method


name: Usually Need Help from Another Person for Hygiene


name: Alternaria alternata specific IgE (lab test)


name: U.S. standard certificate of live birth - recommended 2003 revision set


name: Chlamydia sp tests - FPAR 2.0 set:-:Pt:^Patient:-


name: Coded cause of death - recommended CDA R1 sections


name: Coded cause of death - recommended CDA R1 sections:-:Pt:{Setting}:-


name: Coded race and ethnicity - recommended CDA R1 sections


name: Coded race and ethnicity - recommended CDA R1 sections:-:Pt:{Setting}:-


name: Sexual activity with a new partner in past 60D:PrThr:Pt:^Patient:Ord


name: Chemokine (C-X-C Motif) Ligand 6 Measurement


name: GAIA Neonatal Encephalopathy Level of Diagnostic Certainty Terminology


name: GAIA Neonatal Encephalopathy Level of Diagnostic Certainty


name: Health Assessment Questionnaire Disability Index


name: Herpes simplex virus 1 DNA [Presence] in Cerebral spinal fluid by Target amplification with non-probe based detection


name: World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered Questionnaire


name: NCCN Distress Thermometer and Problem List for Patients Version 2.2016


name: Streptococcus pneumoniae Danish serotype 7A Ab.IgG:ACnc:Pt:Ser:Qn


name: Pap smear tests - FPAR 2.0 set:-:Pt:^Patient:-


name: Blood pressure panel with all children optional


name: Number of sexual partners in last 12Mo:NRat:12Mo:^Patient:Qn


name: Reason vaccine not received:Find:Pt:^Patient:Nom


name: Provider death registration - recommended CDA R1 sections:-:Pt:{Setting}:-


name: Provider death registration - recommended CDA R1 sections


name: Date of last evaluation:Date:Pt:^Patient:Qn


name: Date specimen sent to CDC:Date:Pt:^Patient:Qn


name: Send document that conforms to Level 3 EMS R2 template


name: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES


name: Insulin Aspart Rapid-acting/ Insulin Aspart Protamine


name: Insulin Lispro Rapid-acting/ Insulin Lispro Protamine


name: Product distribution prior to required testing


name: Product distribution prior to validation of process


name: Product distribution prior to quality control unit release


name: Manufacturing stability testing preservative issue


name: Manufacturing stability testing chemical analysis purity issue


name: Manufacturing stability testing moisture issue


name: Manufacturing stability testing pH issue


name: Manufacturing stability testing container closure issue


name: Survival motor neuron 2 gene copy number


name: Topical product difficult to remove from application site


name: Non-haematological malignant tumours (SMQ)


name: Haematological tumours of unspecified malignancy (SMQ)


name: Non-haematological tumours of unspecified malignancy (SMQ)


name: Manufacturing stability testing potency issue


name: {3 (0.8 ML adalimumab 100 MG/ML Auto-Injector) } Pack


name: Calculated Panel Reactive Antibody Measurement


name: nutritional supplement 0.04 gram-1 kcal/mL ORAL LIQUID (ML)


name: nutritional supplement 0.07 gram-1.5 kcal/mL ORAL LIQUID (ML)


name: nutritional supplement 0.08 gram-2 kcal/mL ORAL LIQUID (ML)


name: nutritional supplement/inulin/fructooligosaccharides/fiber 0.05 gram-1.06 kcal/mL ORAL LIQUID (ML)


name: Lidocaine;Lidocaine/Prilocaine 4%; 2.5%-2.5% Multiple Routes Kit [DOLOTRANZ]


name: TITANIUM DIOXIDE 60 mg in 1 mL / ZINC OXIDE 60 mg in 1 mL TOPICAL CREAM [Pure Haven Essentials]


name: ADENOSINE 0.04 g in 100 mL / GINSENOSIDES 0.05 g in 100 mL TOPICAL LIQUID [HERBAL IRON ENRICHED MOISTURE SKIN TONER]


name: ADENOSINE 0.04 g in 100 g / GINSENOSIDES 0.1 g in 100 g TOPICAL CREAM [HERBAL IRON INCREASED NUTRITION]


name: ADENOSINE 0.04 g in 100 mL / NIACINAMIDE 2 g in 100 mL TOPICAL LIQUID [DR. GLODERM TABRX LIFTUP MASK]


name: Adenosine 0.06 g in 150 mL TOPICAL EMULSION [YENAAN JINAEK]


name: Adenosine 0.06 g in 150 mL TOPICAL LIQUID [YENAAN JINAEK TONER]


name: GINSENOSIDES 0.05 g in 100 mL / ADENOSINE 0.04 g in 100 mL TOPICAL EMULSION [HERBAL IRON ENRICHED MOISTURE]


name: GINSENOSIDES 0.1 g in 100 mL / ADENOSINE 0.04 g in 100 mL TOPICAL LIQUID [HERBAL IRON INTENSIVE AQUA SERUM]


name: GLYCERIN 5 g in 100 mL TOPICAL LIQUID [DR. GLODERM TABRX MOISTURE MASK]


name: Niacinamide 0.6 g in 30 g / Adenosine 0.012 g in 30 g TOPICAL CREAM [YENAAN JINAEK EYE]


name: Niacinamide 1.0 g in 50 g / Adenosine 0.02 g in 50 g TOPICAL CREAM [YENAAN JINAEK]


name: Niacinamide 1.0 g in 50 mL / Adenosine 0.02 g in 50 mL TOPICAL LIQUID [YENAAN JINAEK ESSENCE]


name: homosalate 100 mg in 1 mL / oxybenzone 60 mg in 1 mL / octisalate 50 mg in 1 mL / avobenzone 30 mg in 1 mL / octocrylene 20 mg in 1 mL TOPICAL LIQUID [SkinPharmacy Advanced Sun Therapy Broad Spectrum SPF 50 Face]


name: INCONT BRIEF MOLICARE SUPER ABSORBENCY LARGE


name: MULTIDEX HYDROPHILIC WOUND DRESSING PWDR,DEROYAL #46-704,TUBE,6G


name: THICK & EASY (NECTAR) GUM BASED PWDR,PKT,1.4GM


name: TRACH TUBE,SZ 8 CUFFLESS/FENESTRATED SHLY #8-LGT


name: TUBING,SUCTION 1/4IN X 12FT COVIDIEN #8888284620


name: First-Metronidazole 50 7.5g Compounding Kit


name: OCTOCRYLENE 4.5 g in 100 mL / HOMOSALATE 3.5 g in 100 mL / AVOBENZONE 2 g in 100 mL / OCTISALATE 3.5 g in 100 mL TOPICAL LOTION [Eucerin Redness Relief Daily Perfecting]


name: ENROFLOXACIN 1 kg in 1 kg NOT APPLICABLE POWDER


name: GLYCERIN 5 mg in 1 mL / DIMETHICONE 0.55 mg in 1 mL TOPICAL CREAM [Longevity Recovery Moisturizing]


name: triamcinolone acetonide/dimethicone 0.1 %-5 % TOPICAL KIT, OINTMENT AND CREAM


name: GLYCERIN 10 mg in 1 mL TOPICAL CREAM [Longevity Recovery Serum]


name: Resveratrol;Solution, Multi Ingredient NA Multiple Routes Kit


name: OCTISALATE 5 mg in 1 mL / HOMOSALATE 5 mg in 1 mL / AVOBENZONE 2 mg in 1 mL / OCTOCRYLENE 2 mg in 1 mL TOPICAL LIQUID [American Crew All In One Face Balm Broad Spectrum SPF 15]


name: homosalate 40 mg in 1 mL / octisalate 40 mg in 1 mL / avobenzone 20 mg in 1 mL / octocrylene 20 mg in 1 mL TOPICAL LIQUID [Beauty 360 Accelerated Wrinkle Repair Moisturizer]


name: chlorhexidine / miconazole / salicyloyl phytosphingosine


name: Memorial Sloan Kettering Cancer Center Amenity Kit KIT


name: GLYCERIN 6 mg in 1 mL / DIMETHICONE 3.36 mg in 1 mL TOPICAL CREAM [Longevity Recovery Nourishing]


name: Easy Touch Safety Syringe .5 cc 30g 5/16


name: SureComfort Pen 30g, 0.5 cc, 5/16 inches


name: {7 (ethinyl estradiol 0.01 MG Oral Tablet) / 42 (ethinyl estradiol 0.02 MG / levonorgestrel 0.15 MG Oral Tablet) / 21 (ethinyl estradiol 0.025 MG / levonorgestrel 0.15 MG Oral Tablet) / 21 (ethinyl estradiol 0.03 MG / levonorgestrel 0.15 MG Oral Tablet) } Pack [Rivelsa 91 Day]


name: nutritional therapy for phenylketonuria (PKU), no.66 80 gram-334 kcal/100 gram ORAL POWDER IN PACKET (EA)


name: sodium aspartate monohydrate 100 % MISCELL POWDER (GRAM)


name: home hemoglobin A1C monitor MISCELL EACH


name: nutritional therapy, phenylketonuria (PKU), no.66


name: Kendra SKIN PROTECTION and PAIN RELIEF FOR HAIR REMOVAL KIT


name: TITANIUM DIOXIDE 131.9 mg in 1 g / OCTINOXATE 67 mg in 1 g / OCTISALATE 40 mg in 1 g TOPICAL CREAM [JUNGSAEMMOOL Essential Skin Nuder Cushion Medium Deep]


name: OCTINOXATE 7.5 g in 100 g / OXYBENZONE 3.5 g in 100 g / AVOBENZONE 2.5 g in 100 g / OCTISALATE 1.5 g in 100 g TOPICAL LOTION [SLMD Moisturizer with SPF]


name: DIMETHICONE 0.75 mg in 1 mL TOPICAL CREAM [Lightening Clarifying Concentrated Serum]


name: GLYCERIN 30 mg in 1 mL TOPICAL CREAM [Lightening Brightening Moisturizing Serum]


name: AVOBENZONE 30 mg in 1 g / OXYBENZONE 40 mg in 1 g / HOMOSALATE 130 mg in 1 g / OCTOCRYLENE 20 mg in 1 g / OCTISALATE 50 mg in 1 g TOPICAL AEROSOL, SPRAY [CVS Health Baby SPF 50]


name: Titanium Dioxide 2.85 g in 100 mL / Octinoxate 2.14 g in 100 mL / Zinc Oxide 1.61 g in 100 mL / Octisalate 1.43 g in 100 mL TOPICAL CREAM [Dr LeE UV ICE SHIELD]


name: BETHANECHOL CHLORIDE 495 g in 500 g NOT APPLICABLE POWDER [X]


name: CARPROFEN 495 g in 500 g NOT APPLICABLE POWDER [X]


name: Liothyronine Sodium 4.95 g in 5 g NOT APPLICABLE POWDER [X]


name: RUXOLITINIB PHOSPHATE 4.95 g in 5 g NOT APPLICABLE POWDER [X]


name: {1 (35000 MG) (lanolin 0.155 MG/MG / petrolatum 0.534 MG/MG Topical Ointment) / 1 (35000 MG) (lidocaine 40 MG/ML Topical Cream) } Pack


name: GLYCERIN 4 mg in 1 mL TOPICAL CREAM [Age Defense Pro Prebiotic Technology Econature]


name: {21 (desogestrel 0.15 MG / ethinyl estradiol 0.02 MG Oral Tablet) / 5 (ethinyl estradiol 0.01 MG Oral Tablet) / 2 (inert ingredients 1 MG Oral Tablet) } Pack [Simliya 28 Day]


name: Glycerin 0.5 g in 50 mL TOPICAL SPRAY [BODYHOLIC RED POTION HAIR AND BODY MIST]


name: avobenzone 20 mg in 1 g / octinoxate 75 mg in 1 g / octisalate 30 mg in 1 g TOPICAL STICK [Sport Sunstick SPF 30 Sunscreen]


name: OCTINOXATE 7.5 mg in 1 g / OXYBENZONE 4.0 mg in 1 g / OCTOCRYLENE 2.0 mg in 1 g TOPICAL STICK [Amish Origins SPF 15 Lip Balm]


name: LEVOMEFOLATE MAGNESIUM 1 mg / LEUCOVORIN 1 mg / FLAVIN ADENINE DINUCLEOTIDE 1 mg / FLAVIN MONONUCLEOTIDE 2 mg / PYRIDOXINE HYDROCHLORIDE 20 mg / PYRIDOXAL PHOSPHATE ANHYDROUS 5 mg / COBAMAMIDE 500 mg / POTASSIUM IODIDE 250 ug / ZINC GLYCINATE 15 mg / MAGNESIUM OXIDE 125 mg / NADH 25 ug / OMEGA-3 FATTY ACIDS 300 mg / IRON PENTACARBONYL 15 mg ORAL CAPSULE [BumP DHA]


name: {2 (0.4 ML adalimumab 100 MG/ML Auto-Injector) / 1 (0.8 ML adalimumab 100 MG/ML Auto-Injector) } Pack


name: VTSL small animal specialty diagnostic terms reference set


name: VTSL small animal specialty diagnostic terms reference set group


name: regulation of motile primary cilia formation


name: regulation of motile primary cilia assembly


name: meiosis I spindle assembly checkpoint signaling


name: endocannabinoid signaling pathway involved in retrograde trans-synaptic signaling


name: positive regulation of inflammatory response to wounding


name: potassium channel activating, G protein-coupled receptor signaling pathway


name: ion channel modulating, G protein-coupled receptor signaling pathway


name: kainate selective glutamate receptor signaling pathway


name: AMPA selective glutamate receptor signaling pathway


name: NMDA selective glutamate receptor signaling pathway


name: inhibition of host CRISPR-cas system by virus


name: G protein-coupled serotonin receptor signaling pathway


name: envenomation resulting in vasodilation in another organism


name: 2-Dimensional Single Plane Ultrasound Mode


name: AHG-enhanced Complement-dependent Lymphocytotoxicity Assay


name: AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M


name: Ability to Bend Down to Pick up Clothing from the Floor


name: Ability to Lift a Full Cup or Glass to Mouth


name: Ability to Reach and Get Down 5 Pound Object From Above Head


name: Accumulation Ratio AUC Over Dosing Interval Normalized by Dose


name: Accumulation Ratio AUC T1 to T2 Normalized by Dose


name: Accumulation Ratio Cmax Normalized by Dose


name: Accumulation Ratio Cmin Normalized by Dose


name: Accumulation Ratio Ctrough Normalized by Dose


name: Albumin-binding Cisplatin Prodrug BTP-114


name: Alpha-Methylacyl Coenzyme A Racemase mRNA Measurement


name: Alternaria tenuis alternata Antigen IgA Antibody Measurement


name: Alternaria tenuis alternata Antigen IgE Antibody Measurement


name: Alternaria tenuis alternata Antigen IgG4 Antibody Measurement


name: American Cockroach Antigen IgA Antibody Measurement


name: American Cockroach Antigen IgE Antibody Measurement


name: American Cockroach Antigen IgG Antibody Measurement


name: Amino Acid/Electrolyte Mixture-based Dietary Supplement


name: Animal Mix Antigen IgE Antibody Measurement


name: Animal Mix Antigen IgG Antibody Measurement


name: Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse


name: Apoptotic Pathway-targeting Antineoplastic Agent


name: Approved Drug Product Manufactured Under Contract


name: Aspergillus fumigatus Antigen IgE Antibody Measurement


name: Aspergillus fumigatus Antigen IgG Antibody Measurement


name: Associated Persons Demographics Submission Domain


name: Average Concentration from T1 to T2 Normalized by Body Mass Index


name: Average Concentration from T1 to T2 Normalized by Dose


name: Average Concentration from T1 to T2 Normalized by Surface Area


name: Average Concentration from T1 to T2 Normalized by Weight


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1052T>C Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1075T>G Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1150C>A Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1187A>C Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1187A>G Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1457T>C Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.742C>G Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.749G>A Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.756G>C Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.756G>T Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.758A>T Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.763G>A Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.764A>T Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.827A>G Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.835G>A Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.895G>C Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.895G>T Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.949T>C Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.951C>A Mutation


name: BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.951C>G Mutation


name: BUERS - Brooke Upper Extremity Rating Scale


name: Basophil Band Form to Leukocytes Ratio Measurement


name: Bee Mix Antigen IgE Antibody Measurement


name: Bee Mix Antigen IgG Antibody Measurement


name: Bee Mix Antigen IgG4 Antibody Measurement


name: Bifidobacterium animalis/Lactobacillus rhamnosus Probiotic Supplement


name: Bladder Cancer Muscle-Invasive 30 Questionnaire


name: Bothered by Sore Mouth and/or Pain When Swallowing


name: Bowel Function Diary for Assessing Opioid-Induced Constipation


name: Brief Psychiatric Rating Scale - version 4


name: Brooke Upper Extremity Rating Scale Clinical Classification


name: CDISC Clinical Classification BUERS Test Code Terminology


name: CDISC Clinical Classification BUERS Test Name Terminology


name: CDISC Clinical Classification HAM-D6 Clinician Version Test Code Terminology


name: CDISC Clinical Classification HAM-D6 Clinician Version Test Name Terminology


name: CDISC Clinical Classification HAMD 24 Test Code Terminology


name: CDISC Clinical Classification HAMD 24 Test Name Terminology


name: CDISC Clinical Classification IDS-C Test Code Terminology


name: CDISC Clinical Classification IDS-C Test Name Terminology


name: CDISC Clinical Classification KDPI Test Code Terminology


name: CDISC Clinical Classification KDPI Test Name Terminology


name: CDISC Clinical Classification NSAA Test Code Terminology


name: CDISC Clinical Classification NSAA Test Name Terminology


name: CDISC Clinical Classification QIDS-C Test Code Terminology


name: CDISC Clinical Classification QIDS-C Test Name Terminology


name: CDISC Clinical Classification VLERS Test Code Terminology


name: CDISC Clinical Classification VLERS Test Name Terminology


name: CDISC Integrated Basic Data Structure Dataset


name: CDISC Integrated Occurrence Data Structure Dataset


name: CDISC Protocol Entities Physical Address Attribute Terminology


name: CDISC Protocol Entities Study Protocol Attribute Terminology


name: CDISC Questionnaire CES Test Code Terminology


name: CDISC Questionnaire CES Test Name Terminology


name: CDISC Questionnaire EPDS Test Code Terminology


name: CDISC Questionnaire EPDS Test Name Terminology


name: CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology


name: CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology


name: CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology


name: CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology


name: CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology


name: CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology


name: CDISC Questionnaire HAM-D6 Self-Report Version Test Code Terminology


name: CDISC Questionnaire HAM-D6 Self-Report Version Test Name Terminology


name: CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology


name: CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology


name: CDISC Questionnaire IDS-SR Test Code Terminology


name: CDISC Questionnaire IDS-SR Test Name Terminology


name: CDISC Questionnaire Q-LES-Q Test Code Terminology


name: CDISC Questionnaire Q-LES-Q Test Name Terminology


name: CDISC Questionnaire Q-LES-Q-SF Test Code Terminology


name: CDISC Questionnaire Q-LES-Q-SF Test Name Terminology


name: CDISC Questionnaire QIDS-SR Test Code Terminology


name: CDISC Questionnaire QIDS-SR Test Name Terminology


name: CDISC Questionnaire TSQM Version 1.4 Test Code Terminology


name: CDISC Questionnaire TSQM Version 1.4 Test Name Terminology


name: CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology


name: CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology


name: CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology


name: CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology


name: CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology


name: CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology


name: CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology


name: CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology


name: CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology


name: CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology


name: CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology


name: CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology


name: CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology


name: CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology


name: CDISC SDTM Administration Technique Response Terminology


name: CDISC SDTM Asthma Findings About Test Code Terminology


name: CDISC SDTM Asthma Findings About Test Name Terminology


name: CDISC SDTM Diabetic Kidney Findings About Test Code Terminology


name: CDISC SDTM Ebola Virus Findings About Test Code Terminology


name: CDISC SDTM Ebola Virus Findings About Test Name Terminology


name: CDISC SDTM Genetic Region of Interest Type Terminology


name: CDISC SDTM Malaria Findings About Test Code Terminology


name: CDISC SDTM Malaria Findings About Test Name Terminology


name: CDISC SDTM Microscopic Findings Test Code Terminology


name: CDISC SDTM Microscopic Findings Test Name Terminology


name: CDISC SDTM Urinary System Test Code Terminology


name: CDISC SEND Within Normal Limits Results Terminology


name: CES - Ever Combat Patrols or Dangerous Duty


name: CES - In Danger of Being Injured or Killed


name: CES - Soldiers in Unit Killed (KIA), Wounded, Missing (MIA)


name: Cat Dander Antigen IgE Antibody Measurement


name: Cat Dander Antigen IgG Antibody Measurement


name: Cat Dander Antigen IgG4 Antibody Measurement


name: Chemokine (C-C Motif) Ligand 12 Measurement


name: Chemotherapy-induced Nausea and Vomiting Questionnaire


name: Continuous Temperature Monitoring Device


name: Dairy Mix Antigen IgG Antibody Measurement


name: Day Times Microgram per Milliliter Times Kilogram per Milligram


name: Dermatophagoides farinae Antigen IgE Antibody Measurement


name: Dermatophagoides farinae Antigen IgG Antibody Measurement


name: Dermatophagoides pteronyssinus Antigen IgE Antibody Measurement


name: Dermatophagoides pteronyssinus Antigen IgG Antibody Measurement


name: Difficult Getting Enough Sleep Because of Need to Get Up Frequently at Night to Urinate


name: Distress over Physical Problem with Substance Abuse


name: Dog Dander Antigen IgA Antibody Measurement


name: Dog Dander Antigen IgE Antibody Measurement


name: Dog Dander Antigen IgG Antibody Measurement


name: Dog Dander Antigen IgG4 Antibody Measurement


name: Dynamic International Prognostic Scoring System


name: EPDS - Anxious or Worried No Good Reason


name: EPDS - Scared or Panicky for No Good Reason


name: Ebola Virus Specific IgG Antibody Secreting Cell Count


name: Ebola Virus Specific IgM Antibody Secreting Cell Count


name: English Plantain Pollen IgG4 Measurement


name: Epithelial Cells to Total Cells Ratio Measurement


name: European Union Drug Regulating Authorities Clinical Trials Database


name: Extent of Agreement or Disagreement on Career Decisions


name: Extent of Agreement or Disagreement on Conventionality


name: Extent of Agreement or Disagreement on Demonstrations of Affection


name: Extent of Agreement or Disagreement on Religious Matters


name: Extent of Agreement or Disagreement on Sex Relations


name: Eye Dryness Affects Vision or Prevents Working


name: FACT-HEP Version 4 - Able to Do My Usual Activities


name: FACT-HEP Version 4 - Bothered by Jaundice or Yellow Skin


name: FACT-HEP Version 4 - Bothered by Treatment Side Effect


name: FACT-HEP Version 4 - Content With Quality of My Life


name: FACT-HEP Version 4 - Discomfort or Pain in Stomach Area


name: FACT-HEP Version 4 - Enjoy Things I Usually Do for Fun


name: FACT-HEP Version 4 - Get Emotional Support From Family


name: FACT-HEP Version 4 - Had Change in the Way Food Tastes


name: FACT-HEP Version 4 - I Am Able to Enjoy Life


name: FACT-HEP Version 4 - I Am Bothered by Constipation


name: FACT-HEP Version 4 - I Am Forced to Spend Time in Bed


name: FACT-HEP Version 4 - I Am Satisfied With My Sex Life


name: FACT-HEP Version 4 - I Can Digest My Food Well


name: FACT-HEP Version 4 - I Feel Close to My Friends


name: FACT-HEP Version 4 - I Feel Close to My Partner


name: FACT-HEP Version 4 - I Get Support From My Friends


name: FACT-HEP Version 4 - I Have Accepted My Illness


name: FACT-HEP Version 4 - I Have Control of My Bowels


name: FACT-HEP Version 4 - I Have Pain in My Back


name: FACT-HEP Version 4 - I Have a Good Appetite


name: FACT-HEP Version 4 - I Have a Lack of Energy


name: FACT-HEP Version 4 - I Worry About Dying


name: FACT-HEP Version 4 - Losing Hope Against Illness


name: FACT-HEP Version 4 - My Family Has Accepted My Illness


name: FACT-HEP Version 4 - My Work Is Fulfilling


name: FACT-HEP Version 4 - Satisfied With Communication About Illness


name: FACT-HEP Version 4 - Satisfied With How I Am Coping


name: FACT-HEP Version 4 - Swelling or Cramps in Stomach Area


name: FACT-HEP Version 4 - Trouble Meeting Needs of Family


name: FACT-HEP Version 4 - Unhappy About Change in My Appearance


name: FACT-HEP Version 4 - Worry My Condition Will Get Worse


name: FACT-HEP Version 4 Questionnaire Question


name: FACT-LEU Version 4 - Able to Do My Usual Activities


name: FACT-LEU Version 4 - Bothered by Lumps or Swelling


name: FACT-LEU Version 4 - Bothered by Treatment Side Effect


name: FACT-LEU Version 4 - Certain Parts of Body Have Pain


name: FACT-LEU Version 4 - Content With Quality of My Life


name: FACT-LEU Version 4 - Enjoy Things I Usually Do for Fun


name: FACT-LEU Version 4 - Feel Isolated Because of Illness


name: FACT-LEU Version 4 - Get Emotional Support From Family


name: FACT-LEU Version 4 - I Am Able to Enjoy Life


name: FACT-LEU Version 4 - I Am Bothered by Fevers


name: FACT-LEU Version 4 - I Am Bothered by the Chills


name: FACT-LEU Version 4 - I Am Forced to Spend Time in Bed


name: FACT-LEU Version 4 - I Am Satisfied With My Sex Life


name: FACT-LEU Version 4 - I Feel Close to My Friends


name: FACT-LEU Version 4 - I Feel Close to My Partner


name: FACT-LEU Version 4 - I Feel Weak All Over


name: FACT-LEU Version 4 - I Get Support From My Friends


name: FACT-LEU Version 4 - I Have Accepted My Illness


name: FACT-LEU Version 4 - I Have Emotional Ups and Downs


name: FACT-LEU Version 4 - I Have Night Sweats


name: FACT-LEU Version 4 - I Have a Good Appetite


name: FACT-LEU Version 4 - I Have a Lack of Energy


name: FACT-LEU Version 4 - I Worry About Dying


name: FACT-LEU Version 4 - I Worry About Getting Infections


name: FACT-LEU Version 4 - Losing Hope Against Illness


name: FACT-LEU Version 4 - My Family Has Accepted My Illness


name: FACT-LEU Version 4 - My Work Is Fulfilling


name: FACT-LEU Version 4 - Satisfied Communication Illness


name: FACT-LEU Version 4 - Satisfied With How I Am Coping


name: FACT-LEU Version 4 - Trouble Meeting Needs of Family


name: FACT-LEU Version 4 - Uncertain About My Future Health


name: FACT-LEU Version 4 - Worry I Might Get New Symptoms


name: FACT-LEU Version 4 - Worry My Condition Will Get Worse


name: FACT-LEU Version 4 Questionnaire Question


name: FACT-LYM Version 4 - Bothered by Lumps or Swelling


name: FACT-LYM Version 4 - Bothered by Treatment Side Effect


name: FACT-LYM Version 4 - Certain Parts of Body Have Pain


name: FACT-LYM Version 4 - Content With Quality of My Life


name: FACT-LYM Version 4 - Difficulty Planning for Future


name: FACT-LYM Version 4 - Enjoy Things I Usually Do for Fun


name: FACT-LYM Version 4 - Feel Isolated Because of Illness


name: FACT-LYM Version 4 - Get Emotional Support From Family


name: FACT-LYM Version 4 - I Am Able to Enjoy Life


name: FACT-LYM Version 4 - I Am Bothered by Fevers


name: FACT-LYM Version 4 - I Am Bothered by Itching


name: FACT-LYM Version 4 - I Am Forced to Spend Time in Bed


name: FACT-LYM Version 4 - I Am Satisfied With My Sex Life


name: FACT-LYM Version 4 - I Feel Close to My Friends


name: FACT-LYM Version 4 - I Feel Close to My Partner


name: FACT-LYM Version 4 - I Get Support From My Friends


name: FACT-LYM Version 4 - I Have Accepted My Illness


name: FACT-LYM Version 4 - I Have Emotional Ups and Downs


name: FACT-LYM Version 4 - I Have Night Sweats


name: FACT-LYM Version 4 - I Have Trouble Concentrating


name: FACT-LYM Version 4 - I Have Trouble Sleeping at Night


name: FACT-LYM Version 4 - I Have a Lack of Energy


name: FACT-LYM Version 4 - I Have a Loss of Appetite


name: FACT-LYM Version 4 - I Worry About Dying


name: FACT-LYM Version 4 - I Worry About Getting Infections


name: FACT-LYM Version 4 - Losing Hope Against Illness


name: FACT-LYM Version 4 - My Family Has Accepted My Illness


name: FACT-LYM Version 4 - My Work Is Fulfilling


name: FACT-LYM Version 4 - Satisfied With Communication About Illness


name: FACT-LYM Version 4 - Satisfied With How I Am Coping


name: FACT-LYM Version 4 - Trouble Meeting Needs of Family


name: FACT-LYM Version 4 - Worry I Might Get New Symptoms


name: FACT-LYM Version 4 Questionnaire Question


name: Feel Less Feminine or Masculine as a Result of Illness or Treatment


name: Feel Like Doing All Sorts of Nice Things


name: Feel Self-Conscious About Letting Partner See My Breasts


name: Feel Too Tired to Spend Time with Friends


name: Feel Too Tired to do Things I Like to Do


name: Feel Uncomfortable About Sexual Intimacy


name: Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 Questionnaire


name: Functional Assessment of Cancer Therapy-Leukemia Version 4 Questionnaire


name: Functional Assessment of Cancer Therapy-Lymphoma Version 4 Questionnaire


name: G6PD-Deficient Erythrocytes to Erythrocytes Ratio Measurement


name: GAIA Dysfunctional Labor Level of Diagnostic Certainty Terminology


name: GAIA Level 3a Postnatally Diagnosed Congenital Microcephaly


name: GAIA Level 3b Postnatally Diagnosed Congenital Microcephaly


name: GAIA Level 3b Prenatally Diagnosed Congenital Microcephaly


name: German Cockroach Antigen IgA Antibody Measurement


name: German Cockroach Antigen IgE Antibody Measurement


name: German Cockroach Antigen IgG Antibody Measurement


name: German Cockroach Antigen IgG4 Antibody Measurement


name: Global Satisfaction with Sex Life Subordinate Domain


name: Grass Mix Pollen Antigen IgA Antibody Measurement


name: Grass Mix Pollen Antigen IgE Antibody Measurement


name: Grass Mix Pollen Antigen IgG Antibody Measurement


name: Green/Gray Tiger Top Plasma Separation Tube


name: GvHD Body Surface Area Involvement Score


name: HAM-D6 - Clinician Version - Depressed Mood


name: HAM-D6 - Clinician Version - Low Self-esteem and Guilt


name: HAM-D6 - Clinician Version - Psychic Anxiety


name: HAM-D6 - Clinician Version - Psychomotor Retardation, General


name: HAM-D6 - Clinician Version - Social Life Activities or Interests


name: HAM-D6 - Clinician Version - Tiredness and Pains